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Despite recent medical advances, atherosclerosis is a global burden accounting for numerous deaths and
hospital admissions. Immune-mediated inflammation is a major component of the atherosclerotic
process, but earlier research focus on adaptive immunity has gradually switched towards the role of
innate immunity. The complement system and toll-like receptors (TLRs), and the crosstalk between
them, may be of particular interest both with respect to pathogenesis and as therapeutic targets in
atherosclerosis. Animal studies indicate that inhibition of C3a and C5a reduces atherosclerosis. In
humans modified LDL-cholesterol activate complement and TLRs leading to downstream inflammation,
and histopathological studies indicate that the innate immune system is present in atherosclerotic le-
sions. Moreover, clinical studies have demonstrated that both complement and TLRs are upregulated in
atherosclerotic diseases, although interventional trials have this far been disappointing. However, based
on recent research showing an intimate interplay between complement and TLRs we propose a model in
which combined inhibition of both complement and TLRs may represent a potent anti-inflammatory
therapeutic approach to reduce atherosclerosis.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Atherosclerosis e an inflammatory disease
Atherosclerosis is a common disorder and a leading cause of
morbidity and mortality worldwide. In many cases, individuals are
asymptomatic and the disease is therefore not recognized until an
acute thrombotic manifestation like myocardial infarction (MI),
stroke or sudden death occurs. Moreover, the prevalence of
atherosclerotic disease and its related costs are expected to increaseision of Internal Medicine,
Hovland).
Ireland Ltd. This is an open accessnot only in the industrialized but also in developing countries [1]. It
remains a huge challenge to solve this global clinical problem.
Inflammation is a major component of atherosclerosis and
considered to play a role in all developmental stages of the disease
[2,3]. Illustratively, cholesterol and inflammation have been
described as two partners in crime during atherogenesis [4]. Li-
poproteins that are trapped and retained by matrix proteoglycans
in the intimal layer of the arterial wall easily undergo oxidative
modifications, and this event is followed by an immediate innate
immune response [5,6]. The bidirectional interaction between
inflammation and lipids will lead to an accumulation of lipid-filled
macrophages in the intima and eventually form a lipid core not only
including lipid-filled cells but also apoptotic and necrotic cells, cellarticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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favoring smooth muscle cell proliferation and synthesis of extra-
cellular matrix proteins, the lesion will acquire a stable but nar-
rowing phenotype in relation to lumen diameter characterized by
the central lipid core and a thick surrounding layer of smooth
muscle cells and fibrous connective tissue, a so-called fibrous cap.
However, atherosclerosis is a dynamic process and the stable
lesion may be transformed into an unstable, rupture-prone lesion.
In contrast to the stable plaque, a large lipid core and a thin fibrous
cap characterize the unstable plaque. In addition there is consistent
evidence for an imbalance between pro- and anti-inflammatory
mediators towards larger infiltrates of T cells and activated mac-
rophages, higher apoptotic rates and increased expression of pro-
inflammatory cytokines, chemokines and proteolytic enzymes in
unstable plaques. Despite this increasing knowledge of plaque
characteristics, the complex and multifactorial mechanisms behind
plaque destabilization are far from clarified.
Several types of immune cells are involved in the inflammatory
arm of atherosclerosis. Overexpression of T helper 1 (Th1)-derived
cytokines, including interferon (IFN)-g and tumor necrosis factor
(TNF), has been associated with advanced and unstable plaque
phenotypes [7,8]. An excessive Th1 activity is thus considered to
drive the development towards plaque destabilization. On the
other hand, regulatory T cells seem to have atheroprotective
properties by exerting anti-inflammatory and Th1 suppressive ef-
fects. Recently, B cells have also been shown to be involved in
atherogenesis elicting both pro- and anti-atherogenic activities
[9e11]. Thus, while B2 B cells seem to have pro-atherogenic effects,
B1 B cells appear to attenuate the atherosclerotic process at least
partly by secreting interleukin (IL)-10.
Macrophages, prototypical cells in the innate immune system,
have for several years been known to play a key role in lipid
accumulation and inflammation during atherogenesis. These cells
have now been divided into inflammatory (M1) and resolving (M2)
phenotypes [12,13]. Thus while LPS through TLR4 activation and in
combination with IFN-g, released from Th1 cells, promotes M1
polarization, IL-4 and IL13, released from Th2 cells promote M2
polarization of macrophages. More recently, additional sub-
division of M2 macrophages has been performed, i.e. M2a, M2b,
M2c and M2d macrophages [12,13]. A functional classification re-
fers to these M2a macrophages as ‘wound-healing macrophages’.
M2b macrophages are induced upon combined exposure to im-
mune complexes and TLR ligands or IL-1 receptor agonists, pro-
ducing both inflammatory (e.g., IL-6 and TNF) and anti-
inflammatory cytokines (IL-10), M2c macrophages are induced by
IL-10 and glucocorticoids [14]. These M2c macrophages, together
with M2b macrophages, are also referred to as “regulatory mac-
rophages”. Finally, M2d macrophages are induced by co-
stimulation with TLR and adenosine A2A receptor agonists, char-
acterized by high levels of IL-10 and vascular endothelial growth
factor (VEGF), potentially playing a role in angiogenesis. In the
atherosclerosis field, additional forms have been described
including the Mhemmacrophage, consistent with their presence in
regions of haemorrhage [15], and M4 macrophages that are
induced by CCL4 showing high expression of matrix metal-
loproteinases associated with plaque destabilization in carotid
plaques [16]. M1 polarization is induced by TLR2 and TLR4 activa-
tion in combination with lipids. Th2 related cytokines and not TLR
activation seem to be of importance for M2 macrophage polariza-
tion. Like TLRs, complement activation has been linked to M1 po-
larization and C3 deficient mice have been shown to have fewerM1
macrophages and more M2 macrophages [17].
Indeed several components of innate immunity including the
complement system and TLRs, as mentioned above, have increas-
ingly been targeted in atherosclerosis research [3,18]. Oxidativelymodified lipoproteins in the arterial wall are potentially dangerous
stressors. The innate immune system is initiating and orchestrating
the elimination of these particles. In this “first line defence” a va-
riety of pattern-recognition receptors (PRRs) are used including
cellular PRRs such as scavenger receptors and TLRs, and soluble
PRRs such as complement components and germline naturally
occurring IgM antibodies. The innate immune response not only
involves immediate pro-inflammatory actions, but also initiation of
adaptive immunity and resolution of inflammation and tissue
repair. The production of natural IgM antibodies to oxidation-
specific epitopes by naïve B cells is one potential atheroprotective
effect generated by the innate immune system [19,20].
A chronic exposure to stressors in the arterial wall may even-
tually lead to a loss of immune homeostasis. TLRs and complement
are mediators bridging danger sensing further to adaptive immu-
nity, thereby acting as key regulators in the maintenance of im-
mune homeostasis. The complement system has important
regulatory effects on both B cells and T cells [21,22]. Previous re-
views have either addressed the interaction between TLRs and
atherosclerosis [23e26] or between complement and atheroscle-
rosis [27e29]. However, recent research indicates an extensive
crosstalk between TLRs and complement, thus proposing a complex
interplay between these pathways of innate immunity in athero-
genesis. As discussed in the present review, this may open up for
therapeutic strategies favoring the repair process and stabilization
of atherosclerotic lesions.
2. The complement system
The complement system (Fig. 1) is part of our innate defence
against infections, and was initially described in the late 19th
century [30]. It consists of more than 40 membrane bound and
soluble proteins, the latter mainly being secreted by hepatic cells,
monocytes and macrophages [31,32]. The traditional view of
complement as being predominantly a host defence system against
microbes has expanded markedly the last decades to our current
knowledge that complement is a surveillance system that quickly
can be activated by sensing any danger to the host and thereby
contribute to maintaining tissue homeostasis and promote tissue
regeneration and repair [33]. On the other hand, undesired or un-
controlled activation of the system can induce tissue damage and
organ dysfunction in the host. Forty years ago the interplay be-
tween atherosclerosis and the complement system was suggested
[34], and the theory has later been maintained [29,35].
2.1. Activation pathways
Traditionally there are three known ways through which the
complement system is activated (Fig. 1). The classical pathway (CP)
is activated by C1q binding to antibodies when bound to their an-
tigen, or antibody independent by other recognition molecules like
the pentraxins including C-reactive protein (CRP), serum amyloid
component P (SAP) and long pentraxin 3 (PTX3). The lectin
pathway (LP) is activated when proteins like mannose-binding
lectin (MBL), the ficolins (1, -2 and 3) and collectin-11 recog-
nize their ligands like sugar molecules on microbes, on dying host
cells or on a subendothelial matrix [36,37]. The alternative pathway
(AP) is continuously undergoing a low-grade activation due to hy-
drolysis of the internal C3 thiol-ester bond, and further activated
when there is an imbalance between activation and inhibition e.g.
on foreign surfaces or structures lacking complement regulatory
proteins.
The different activation pathways lead to the common pathway
with activation of C3 and C5 (Fig. 1). From this point the cascade
continues to the terminal pathway with release of the biologically
Fig. 1. The complement system. The complement system can be activated through three pathways, all converging to the cleavage of C3 to generate C3a and C3b. In the classical
pathway (CP) C1q can bind to antibodies, but also pentraxins including C-reactive Protein (CRP), serum amyloid P component (SAP) and pentraxin 3 (PTX3). The Lectin pathway (LP)
is activated through recognition of carbohydrates by mannose binding lectin (MBL), ficolins and collectin-11 (CL-11). Furthermore LP activation may be mediated through IgM
antibodies, e.g. directed against damaged self antigens. The alternative pathway (AP) is activated by foreign or damaged own cells, facilitated by the continuous spontaneous
hydrolysis of C3. AP also has an important function in the complement system providing an amplification loop enhancing C3 activation independent of which pathway that is
initially activated. This effect is mainly due to properdin (P), the only positive regulator in the complement system, which stabilizes the C3 convertase. Activation of C3 leads to
formation of a C5 convertase, cleaving C5 into C5a and C5b. The anaphylatoxins C3a and C5a bind to the receptors C3aR, C5aR1 (CD88) and C5L2 (C5aR2), leading to downstream
production of inflammatory mediators. C5b initiates the formation of the terminal C5b-9 complement complex (TCC), which either forms the membrane attack complex if inserted
into a membrane. This may lead to lysis of bacteria and cells, or in sublytic doses to activation of cells. The cleavage and inactivation of C3b generates iC3b, binds to complement
receptors CR3 (CD11b/CD18) and CR4 (CD11c/CD18), facilitating phagocytosis, oxidative burst and downstream inflammation. The complement system is tightly regulated by soluble
inhibitors, including C1-inhibitor (C1eINH), factor H (FH), factor I (FI), C4-binding protein (C4BP), carboxy-peptidase N (CPN), vitronectin (VN) and clusterin (Clust.), keeping the
continuous low-grade activation in the fluid phase in check. Host cell membranes are equipped with a number of inhibitors to protect them against attack by complement, including
membrane cofactor protein (MCP; CD46), complement receptor 1 (CR1) (CD35), decay accelerating factor (DAF; CD55), controlling C4 and C3 activation, and CD59 protecting against
final assembly of the C5b-9 complex.
A. Hovland et al. / Atherosclerosis 241 (2015) 480e494482highly potent anaphylatoxin C5a and formation of the terminal
C5b-9 complement complex (TCC). The terminal complement
complex can appear as a soluble complex in the fluid phase (sC5b-
9) if there is no adjacent surface to be attacked. sC5b-9 is formed by
assembly of C5b-9 together with the regulators vitronectin and
clusterin, keeping the complex soluble, sC5b-9 is a useful marker
for complement activation in body fluids. If C5b-9 is formed on a
membrane, the membrane attack complex (MAC) is formed. The
latter may either lead to lysis of bacteria and cells by penetrating
the membrane after binding C8 and additional C9 molecules, or, ifformed in sublytic amounts, to stimulation of the cell to release
inflammatory mediators [38]. With relevance to atherosclerosis,
coagulation factors like plasmin, thrombin and other proteases
have in recent years emerged as direct activators of C3 or C5, cir-
cumventing the initial pathways [39e42].
2.2. Complement regulators
As the complement system is both rapid and potent and com-
ponents like C1q and C3 undergo a low-grade spontaneous
A. Hovland et al. / Atherosclerosis 241 (2015) 480e494 483activation, there is a need for strict inhibitory regulation of the
system. These regulators, of which there are both soluble and
membrane-bound types, act in different steps of the complement
cascade (Fig. 1). The C1-inhibitor (C1eINH) and C4b-binding pro-
tein (C4BP) control both CP and LP, the AP is inhibited by factor H
(FH), while factor I (fI) acts in all three pathways. Several membrane
bound receptors including complement receptor 1 (CR1; CD35),
membrane co-factor protein (MCP; CD46) and decay-accelerating
factor (DAF; CD55) inhibit at the level of C3 and thus contribute
to keeping all the initial pathways under control when they
converge at C3. The anaphylatoxins C3a and C5a are inhibited by
carboxypeptidase-N, whereas protectin (CD59) inhibits the for-
mation of TCC. The regulators are of crucial importance in order to
maintain complement homeostasis. Lack of or dysfunctional regu-
lation is often associated with a clinical disease; e.g. atypical hae-
molytic uremic syndrome (aHUS) or membranoproliferative
glomerulonephritis type II (dense deposits disease) when FH is
missing or dysfunctional [43], and paroxysmal nocturnal hemo-
globinuria (PNH) when CD55 and CD59 are missing [44]. This il-
lustrates an important principle of complement activation, namely
that the system can be activated without any specific activator, the
loss of an inhibitor is enough to trigger the system, leading to tissue
damage and disease.
2.3. Clinical use of complement inhibitors
The complement regulator C1eINH has been in clinical use for a
long time as substitution therapy in hereditary angioedema, a
condition with life-threatening recurrent swellings due to low
C1eINH concentrations [45]. The pathophysiology is due to bra-
dykinin formation through the kallikrein-kinin system, in which
C1eINH also plays a crucial role. Thus, C1eINH is not a specific
complement regulator, but participates in several cascade systems.
A novel approach for complement therapy in the clinic is to use a
specific complement inhibitor with the aim of reducing the adverse
effects induced by pathological complement activation. PNH is a
condition where red cells are lysed since they lack complement
regulators on their surface. Blocking C5 by a monoclonal antibody,
eculizumab, was first FDA-approved for treatment of PNH patients
[46]. By blocking cleavage of C5, the anaphylatoxin C5a and the lytic
C5b-9 complex are not formed (Fig. 1). Recently, eculizumab was
also approved for the treatment of aHUS, and it is likely that more
indications will emerge in the areas of kidney disease and trans-
plantation medicine. Side effects of continuous C5 inhibition
include increased susceptibility to Neisseria infections, in the same
manner as patients with C5 deficiency, who otherwise are healthy
[47,48]. The therapeutic potential of complement manipulation in
various diseases has recently been reviewed [49].
Specific complement inhibition has also been used in cardio-
vascular diseases, with promising results in animal models [50],
but, as will be presented below, without convincing clinical results
so far [51,52]. However, studies with inhibition of several comple-
ment factors simultaneously, or the combination of complement
and TLR-system inhibition is yet to be performed.
3. Toll-like receptors
The human innate immune system serves as a first line of
defence, and includes a magnitude of proteins and receptors in
addition to the complement system. Humans have membrane-
bound receptors including TLRs and cytoplasmic sensors
including NOD-like receptors, pyrin and HIN domaine-containing
family members and Rig-I-like receptors [53]. TLRs recognize
exogenous and endogenous stimuli [54]. The exogenous, “non-self”
inducers of these receptors are labeled pathogen associatedmolecular patterns (PAMPs), and the endogenous “self” counter-
part are called damage associated molecular patterns (DAMPs) or
alarmins. The current view is that the main task of the innate im-
mune system is to detect danger, and not simply to discriminate
between “self” and “non-self” [55]. TLRs are PRRs localized on a
variety of different cell types including neutrophils, monocytes/
macrophages, mast cells, T- and B-cells, but also endothelial and
smooth muscle cells [56]. TLRs are phylogenetically old, and in
humans there are at least 10 different TLR proteins, while the
number and types vary between different mammals [57]. They are
all classified as type 1 transmembrane proteins, and except for TLR3
they all use the adaptor molecule Myeloid Differentiation Factor 88
(MyD88) for intracellular signaling and activating transcription of
pro-inflammatory genes. TLR4 signaling can be initiated both
throughMyD88 dependent and independent pathways (Fig. 2). The
MyD88-dependent pathway rapidly activates NF-kB and mainly
takes place at the plasma membrane [58,59], whereas the MyD88-
independent pathway activates interferon regulatory factor-3
(IRF3) and occurs at early endosomes [60,61]. TLR2 is activated
through a MyD88 dependent signaling mechanisms (Fig. 2), how-
ever, recent studies have revealed a novel role for TRAM and TRIF
also for some TLR2 responses [62]. Importantly, there are several
endogenous ligands that can activate TLRs in atherosclerosis.
Different types of heat shock proteins have been reported to
stimulate both TLR2 and TLR4 [63e67]. Another DAMP that can be
released from necrotic cells is high-mobility group box 1 protein
(HMGB1), which initiates signaling both through TLR2 and TLR4
[68e70]. Lipids can also act as TLR ligands and oxidized LDL has
been reported to signal both through TLR2 [71] and through CD36/
TLR4/TLR6 [72]. Comprehensive reviews on endogenous TLR li-
gands of relevance for atherosclerosis can be found in ([26,73]). It
should be kept in mind, when evaluating results from experiments
regarding ligands for TLRs, that contamination with LPS is a ubiq-
uitous source of misinterpretation [74].
TLR1, TLR2, TLR4, TLR5 and TLR6 are located on the plasma
membrane and can be activated by a whole array of ligands
including bacterial cell wall components (e.g. lipopolysaccharide
[LPS] and lipoproteins) [75]. TLR3, TLR7, TLR8, and TLR9 are
sequestered in the endoplasmic reticulum and are delivered to the
endosomes, where they encounter and respond to endogenous and
exogenous DNA and RNA. Once inside the endosomes, the N-ter-
minal region of the TLRs is processed by multiple lysosomal pro-
teases, including cathepsins and asparagine endopeptidase, to
generate functional receptors that elicit signaling [75]. TLRs have a
number of co-receptors, of which CD14 is of particular interest
since it interacts with several of the TLRs, including TLR2, TLR3,
TLR4, TLR6, TLR7, and TLR9 [76]. Recently it was demonstrated that
modified LDL induces cytokine release, mediated by TLR4 and
CD14, indicating possible therapeutic potential [77].
The prototypical inflammatory cytokine IL-1b as well as IL-18
are processed from their pro-forms via caspase-1 activation to
their active form through assembly of inflammasomes, of which the
NOD-like receptor with a PYD-domain (NLRP)3 inflammasome is
the best characterized [53]. Fully activation of NLRP3 resulting in
mature IL-1b and IL-18 requires two signals [78]. The first signal is
transcription of pro-IL-1b and pro-IL-18 that is induced by NF-kB
activation often downstream of a TLR-ligand interaction. The sec-
ond signal is activation of the inflammasome that results in
caspase-1 activation and maturation and release of IL-1b and IL-18.
Numerous DAMPs and PAMPs activate the inflammasome complex
including various types of crystals, and recently cholesterol crystals
were found to be potent activators of NLRP3 inflammasomes [79].
Cholesterol crystals are frequently found in atherosclerotic lesions
[80], and this phenomenon has until recently been thought to
develop late in the disease. However, minute cholesterol crystals
Fig. 2. Toll-like receptor (TLR) signaling illustrated by TLR2 and TLR4. The membrane bound TLR2 (associated either with TLR1 or TLR6) and TLR4 react with ligands including
pathogen-associated molecular patterns (PAMPs), like lipoproteins for TLR2 and lipopolysaccharides (LPS) for TLR4, and damage-associated molecular patterns (DAMPs), like
oxidized LDL (OxLDL), high-mobility group box 1 protein (HMGB1) and heat shock proteins (HSP) for both receptors. These two TLRs interact with their co-factor CD14 and TLR4-
signaling is also dependent on myeloid differentiation factor 2 (MD-2). Then the adaptor proteins myeloid differentiation primary-response protein 88 (MyD88) and MyD88
adaptor-like (MAL) are engaged. TLR4 signaling may also occur from endosomes where TLR4 interacts with TIR-domain-containing adapter-inducing interferon-b (TRIF) and TRIF-
related adaptor molecule (TRAM) activating interferon regulatory factor 3 (IRF3) via TNF receptor-associated factor (TRAF) 3 leading to the production of pro-inflammatory cy-
tokines downstream. The MyD88 dependent pathway is dependent on IL-1R-associated kinases (IRAKs), TRAFs, several regulatory proteins and transcription factors. Endosomal
TLR4 (MyD88 independent) may also interact with TRAF6 via TRIF and receptor-interacting protein 1 (RIP1). AP1: activator protein 1, CREB: cyclic AMP-responsive element-binding
protein, IKK: inhibitor of NF-kB kinase, JNK:c-jun N-terminal kinase, MKK: MAP kinase kinase, NF-kB: nuclear factor-kB, TAB: TAK1-binding protein, TBK1: TANK-binding kinase 1.
A. Hovland et al. / Atherosclerosis 241 (2015) 480e494484are present in early high fat-diet induced atherosclerotic lesions in
ApoE deficient mice and their appearance coincides with infiltra-
tion of inflammatory cells [79].
It has been shown that CD36 mediates uptake of oxLDL leading
to crystal formation [81]. Moreover, CD14 is important in uptake of
minimally modified LDL that also leads to crystal formation, albeit
to a lesser extent than oxLDL [81]. These studies suggest newmolecular targets, such as the NLRP3 receptor complex and IL-1b,
for therapy against atherosclerosis. Recently a phase II trial
confirmed anti-inflammatory effect of IL-1b inhibition in patients
with type 2 diabetes and high cardiovascular risk as both CRP and
IL-6 levels were significantly reduced by this treatment [82].
Challenging this concept, a recent study in mice found that IL-1a, in
contrast to IL-1b, is the central mediator of atheromatous
A. Hovland et al. / Atherosclerosis 241 (2015) 480e494 485inflammation [83]. There are, however, no data supporting that this
is the case in humans.
4. Crosstalk between complement, the TLRs and other
systems relevant to atherosclerosis
The complement system and the TLRs are both parts of the
innate immune system and hence mediate the hosts “rapid
response” to danger. Crosstalk, in this instance indicating interac-
tion between different arms of innate immunity, the complement
system and TLRs, has been described in several reviews [84e87]. By
using nature's own human knock out, a genetic C5 deficient indi-
vidual, we have previously determined the relative role of C5 and
CD14 in the inflammatory response to Gram-negative bacteria [47].
Although interactions between these systems are barely studied in
atherosclerosis, it is reasonable to suggest that such crosstalk is of
importance in the pathogenesis of this condition as well.
The crosstalk between complement and TLRs involve both
positive and negative feedback mechanisms. Additive and syner-
gistic effects between complement and TLRs occur at several levels,
and such potentiated inflammatory responses may be beneficial for
the host in certain circumstances, including local protection against
infections. This response may, however, be detrimental for the host
if inappropriate and overwhelming, or if occurring systemically;
thus be an attractive target for therapy [86]. A close interaction
between TLR- and C5a receptor-activation has been described
[88e90], and recently we showed that there was not only an ad-
ditive but even synergistic effect on a number of inflammatory
mediators when both complement and the TLR co-receptor CD14
were inhibited in combination as compared to separate inhibition
[91]. Moreover, mice lacking DAF, an inhibitor of the C3 convertases
leading to less C3a and C5a generation, are hypersensitive to TLR
stimulation (TLR4, TLR2/6 and TLR9), suggesting a central role for
complement in the outcome of TLR activation [92] (Fig. 3). The
crosstalk is also bidirectional, and TLR activation has in both in vitro
and in vivo studies been shown to potentiate the effects of C5a. Raby
et al. have demonstrated that TLR activation enhanced C5a-induced
pro-inflammation responses [90]. This was paralleled by a TLR
mediated down-regulation of C5aR2, which serves as a regulator of
C5aR1, thus sensitizing C5aR1 for stimulation with C5a, further
increasing the inflammatory response (Fig. 3) [90].
Complement factor B, a component in the AP, has also emerged
as an important effector of the responses to TLR activation. In a
model of polymicrobial sepsis, factor B was markedly increased in
serum and upregulated in several organs including the heart. This
effect was dependent on the TLR and IL-1 receptor signaling
adaptor MyD88. Importantly, deletion of factor B had marked
protective effects in this model [93].
Complement receptor 3 (CR3) consists of the integrin CD11b and
CD18 and is centrally involved in phagocytosis. CD11b takes part in
negative regulation of TLR-signaling through crosstalk withMyD88,
rendering mice more susceptible to septic shock [94,95], further
underlining the close link between complement and TLRs (Fig. 3).
Thus, the crosstalk between complement and TLRs may be a potent
trigger of further inflammatory loops (Fig. 3) [96]. A dysregulated
interaction between the complement system and TLRs could
therefore not only lead to inappropriate inflammatory responses
during the acute phase, but could also contribute to maintaining a
state of non-resolving inflammation as in atherosclerosis.
Complement factors have recently been reported to promote
NLRP3 activation [97]. Asgari et al. showed that C3a potentiates
LPS-induced NLRP3 inflammasome activation in monocytes by
regulating the efflux of ATP into the extracellular space [98].
Recently, we showed in ex vivo human model systems that
cholesterol crystals induce complement activation through CP,which leads to cytokine release, production of reactive oxygen
species and activation of the inflammasome [99]. These effects
were highly complement-dependent, underscoring complement as
an upstream mediator of cholesterol-induced inflammation.
The concept of inflammation in atherosclerosis is firmly estab-
lished, though still not fully clarified. Increased understanding of
the interplay between complement system and TLRs may add
important knowledge. Based on the possibility to modulate this
interaction at several levels, it is tempting to hypothesize that these
systems and their bidirectional interaction could be promising
targets for therapy in atherosclerotic disorders (Fig. 3).
There is also an extensive crosstalk between the complement
system and the coagulation cascade [100], and among others factor
Xa, thrombin and plasmin may activate the complement cascade
producing C3a and C5a and inducing an inflammatory response
[39,42,101]. Several links for crosstalk between complement and
platelets have also been shown [102]. Furthermore oxidized LDL-
cholesterol may trigger generation of tissue factor through TLR4-
6 heterodimer dependent on CD36 [72,103]. The linking together
of several systems including the haemostatic systems, lipids and
innate immunity, including crosstalk within, could be attractive
targets for therapy in atherosclerosis. Recent evidence that C3 plays
an important role in lipid metabolism, obesity and diabetes type 2
emphasizes this view [104].
Microbial pathogens have acquired highly complex ways to
manipulate the host's innate immunity [105,106]. More precisely
the pathogens may interact with innate immunity receptors,
modulating downstream inflammatory signaling [105]. Hence, it
should be possible to exploit this evolutionary trait in therapy
addressing inflammation. Our group has demonstrated that com-
bined inhibition of the complement system and TLRs, more spe-
cifically combined inhibition of the TLR co-receptor CD14 and
complement inhibitors of C3 and C5, has a remarkable inhibitory
effect of the inflammatory reaction induced by both a number of
danger signals both in animal models and in human ex vivomodels
[47,87,99,107e110]. A future goal would be to test the hypothesis of
double-blockade in a human model of atherosclerosis.
Ischemia reperfusion injury is known from coronary artery
disease, one of the common end stages of atherosclerosis, in which
reperfusion of an occluded artery leads to damage to the tissues
downstream [111]. Similarly, the ischemia reperfusion injury
occurring in renal transplantation is a serious problemwith respect
to graft survival [112]. Crosstalk between the complement system
and TLRs is seen in renal ischemia reperfusion injury, and
furthermore the two systems seem both to be upregulated after
brain death of the donor [113], supporting an important link be-
tween the neuro-endocrine systems and innate immunity. The role
of ischemia in the development of atherosclerosis should be
considered and models should be developed to study the crosstalk
of complement and TLR inhibition.
MicroRNAs (miRNAs) are small non-coding RNA particles
important in regulating protein synthesis. Distinct types of miRNAs
may affect innate immunity, and specifically miR-146a is shown to
be a negative regulator of TLR signaling, which could be of impor-
tance in neurodegenerative diseases [114]. Another miRNA, miR-
155, may affect the complement system by attenuating FH in a
human cell model of Japanese encephalitis [115]. Lastly, the com-
plement system may affect miRNAs. In a mouse model of brain
endothelial cells in systemic lupus erythematosus, C5a seems to
regulate miRNA expression [116]. MiRNAs are attractive targets for
therapeutic intervention, and currently several research projects
address miRNAs, also in lipoproteins and atherosclerosis [117].
Since there seems to be a connection between innate immunity and
miRNAs, this connection should also be further explored in the field
of atherosclerosis.
Fig. 3. Potential role for inhibition of innate immunity in atherosclerosis. The atherosclerotic plaque (panel A) is characterized by immune cells including monocytes, macrophages,
granulocytes, T-cells and foam cells. LDL-cholesterol is retained in the intima where it is oxidized or otherwise enzymatically modified. There is also formation of cholesterol crystals
known to activate the innate immune system. The changes in the vessel wall induce innate immune activation through pattern recognition receptors including toll-like receptors
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Much of the current knowledge in atherosclerosis has been
obtained through animal experiments. Murine models have
obvious advantages including reproducibility, knockout options,
availability and cost. Even if mice are not men, and murine
atherosclerosis is not human atherosclerosis (e.g. mice do not
develop unstable coronary lesions), murine models can integrate
research in lipidology and atherosclerosis as well as the immune
system and provide us with important basic knowledge [118].
The complement system is important in murine models of
atherosclerosis, and examples are shown in Table 1 (References are
given in the table). Activation through CP may be protective
consistent with the role of C1q and the classical pathway being
important for tissue homeostasis by clearance of cell debris and
immune complexes. AP activation, on the other hand, may be pro-
atherogenic due to activation of C3 and subsequent terminal
pathway activation, whereas the role of LP is less elucidated. Irre-
spective of the direct effect of the initial pathways, it seems that
activation of C3 and beyond is detrimental to the vessel wall. Thus,
both C3a and C5a have inflammatory effects in atherosclerosis, and
inhibiting their respective receptors seems promising in murine
models. Several of the studies referred to in Table 1 underscore the
importance of CD59 in protection against atherosclerosis, sup-
porting the hypothesis that C5b-9 formation is important in the
pathogenesis, either through cell lysis or through sublytic inflam-
matory effects. Furthermore, complement inhibitors like CD55 and
CD59 have anti-atherogenic effects in murine models through
altered lipid handling and foam cell formation [119]. In rabbits,
complement C6 deficiency protects against atherosclerosis in rab-
bits [120]. However, the demonstration that C6-deficient rabbits
fed a high-cholesterol diet are protected against atherosclerosis,
whereas atherosclerosis-prone ApoE/mice crossbred with C5-
deficient mice are not protected [121], underlines the limitations
of animal studies and the need for robust human studies.
Cholesterol crystals have been known for decades to activate the
complement system [122]. In a human whole blood model we
recently showed that the cholesterol crystal-induced cytokine
response was totally dependent on complement activation [99]. A
limitation of this model with respect to atherosclerosis is the lack of
endothelial cells. We therefore developed a novel human whole
blood model where endothelial cell activation could be studied
[123]. When cholesterol crystals were incubated in whole blood on
a monolayer of endothelial cells, we found that complement acti-
vation was critically important as initial event for the endothelial
cell activation, and that the activation was mediated by secondary
release of TNF. Despite that this is an ex vivo model with its limi-
tation as such, the data support the notion that complement may
play an important role in human atherosclerosis.
Several TLRs, especially TLR4 and other CD14-dependent TLRs,
are central in the development of murine atherosclerosis. Some
TLR-signaling pathways display anti-atherosclerotic properties,
consistent with a complex inflammatory network with partially
counteracting functions, and examples of studies on TLR-signaling
are shown in Table 2. An example of this complexity, which also
involves interaction with adaptive immunity, was the study by
Subramanian et al. which showed that the suppressive effect of
regulatory T cells on murine atherosclerosis was dependent on
MyD88 signaling in dendritic cells [124]. Yu et al. broadened theand the complement system. These systems cross-talk extensively (panel B, bottom) includin
a membrane inhibitor of C3 activation, cross-talks with several TLRs including TLR4, TLR2
receptor 3 (CR3, CD11b/18), a main receptor for phagocytosis, inhibits TLR signaling by inte
leads to enhanced C3aR response and to a reduced C5aR2 response [22]. The latter implie
response to C5a.understanding of MyD88 dependent signaling, demonstrating that
the interplay between myeloid and endothelial cells in obesity
associated inflammatory diseases including atherosclerosis, is
MyD88 dependent [125].
Although these are animal data, and cannot be immediately
extrapolated to humans, since “mice are not men” [126], they can,
however, still be used to generate hypotheses for further testing in
human models.
6. Complement and TLR in human atherosclerosis
6.1. Modified LDL-cholesterol and innate immune response
LDL-cholesterol is an established risk factor in atherosclerosis,
and amajor player in the development of the atherosclerotic plaque
[127]. In the intima, the trapped LDL particles are oxidized (oxLDL)
and enzymatically modified (E-LDL) facilitating uptake by the
macrophages. Bhakdi et al. have demonstrated that E-LDL binds to
CRP triggering complement activation in human atherosclerotic
lesions [128,129]. In a human macrophage model, it was demon-
strated that C1q and MBL bind to modified lipoproteins including
oxLDL and enhanced macrophage uptake of these lipoproteins
[130]. Furthermore, in the presence of C1q and MBL, an increased
efflux of cholesterol to ATP-binding cassette transporters and HDL-
cholesterol was demonstrated, indicating possible protection
against early atherosclerosis.
In a human leukocyte model, modified LDL led to an increase in
TLR4, as well as TLR2 and CD14, inducing an inflammatory response
including tumor necrosis factor (TNF) formation [131]. Su et al.,
who discovered that oxLDL triggered TLR4 and TLR2, extended this
finding [132]. Exploring the pathways of inflammation in cell cul-
tures, it was found that pro-inflammatory cytokine production was
induced through TLR4 signaling, also underlining the importance of
the Src family kinases [133]. In a combined model including cell
cultures and animal research, it was demonstrated that oxLDL-
cholesterol leads to tissue factor (TF) expression via TLR4 and
TLR6 signaling, hence suggesting a TLR mediated link between
lipids and thrombus formation [103]. A recent study documented
crosstalk between complement and TLRs in this interaction be-
tween lipids and innate immunity as oxLDL increased C3 produc-
tion in human macrophages via activation of TLR4 [134].
Thus, the evidence points to a close interaction between oxLDL,
E-LDL and innate immunity as demonstrated by studies in human
cell cultures, possibly indicating therapeutic targets in early
atherosclerosis formation.
6.2. Innate immune activation in human atherosclerotic tissues
Coronary arteries with atherosclerotic lesions differ from
normal coronary arteries in that they express the anaphylatoxin
receptors C3aR and C5aR1 [135]. There are two C5a receptors,
C5aR1 (CD88) and C5aR2 (C5L2). Vijayan et al. noted prominent
expression of C5aR2 in advanced human atherosclerotic plaques,
and C5aR2 correlated with high levels of pro-inflammatory cyto-
kines [136]. C3a and C5a have also been demonstrated in stenotic
aortic valves as part of an inflammatory response [137]. Comple-
ment inhibitors have been found in stenotic aortic valves, but not in
amounts sufficient to inhibit complement activation and deposition
[138].g both positive and negative feedback mechanisms. E.g. decay accelerating factor (DAF),
/6 and TLR9, leading to reduced responses from C3aR and C5aR1 [92]. Complement
rfering with MyD88 [94,95]. Furthermore, TLR activation (TLR2, TLR4, TLR6 and TLR9)
s an enhanced effect of C5aR1, due to the counterbalance of C5aR1 and C5aR2 in the
Table 1
Selected experimental studies documenting the role of the complement system in atherosclerosis.
Author, year, ref Animal model Intervention Major Endpoint Major finding
Bhatia, 2007 [185] Ldlr.C1qa/ mice Normal or high-fat diet Aortic atheroma size
and apoptotic cells
Increased aortic atheroma and reduced
apoptotic cell clearance in Ldlr.C1qa/ mice.
Lewis, 2009 [186] C1qa.sIgM.Ldlr/ mice Low- and high-fat diet Aortic atheroma size Increased aortic atheroma in sIgM.Ldlr/
mice, indicating IgM protection, independent
of classical pathway
Matthijsen, 2009 [187] Ldlr/ mice High-fat diet Presence of MBL MBL is present in early but not late
atherosclerotic lesions
Orsini, 2012 [188] Mice/rats Cerebral artery occlusion
and MBL inhibition
Presence of MBL cerebral infarct MBL is present in ischemic areas and MBL/
and MBL inhibited animals are protected
Malik, 2010 [189] Bf.Ldlr/ mice Low-fat diet LPS Aortic atheroma size Aortic root atheromas were larger in Ldlr/
compared to Bf.Ldlr/




C5aR blocking inhibited neo-intima formation
and reduced inflammation
Manthey, 2011 [190] ApoE/ mice CD88 antagonist CD88 and C5L2 expression
and aortic atheroma size
CD88 antagonism reduced atheroma size
Lu, 2012 [175] Ldlr.Apob58/ Immunization with
peptides located at C5aR
Aortic atheroma size Immunization reduced atheroma size
Sakuma, 2010 [191] Daf1/ mice Femoral artery injury Leukocyte accumulation
and neo-intima thickening
Enhanced Leukocyte accumulation and
neo-intima thickening in Daf1/ mice
Lewis, 2011 [192] ApoE.CD55/ mice High-fat diet Brachiocephalic atheroma
and lipid profile
ApoE.CD55/ mice were protected from
atherosclerosis due to better lipid profile




ApoE.mCd59 ab / had advanced
atherosclerosis compared to ApoE/ mice,
and this response was attenuated by
anti-mouse C5 antibodies.
Liu, 2014 [193] mCd59 abþ/þ/Apoe/ and
mCd59 ab//Apoe/ mice
CR2-Crry Aortic atherosclerosis Complement inhibition with CR2-Crry
protected mice against atherosclerosis
Abbreviations: Ldlr: LDL-receptor. C1qa: complement factor C1qa (classical activation). sIgM: serum-immunoglobulin-M. MBL: mannose binding lectin. Bf: factor B (alter-
native activation). LPS: lipopolysaccharide (bacterial). ApoE: apolipoprotein E. C5aR: complement factor 5a receptor (C5aR1). CD88: C5a-receptor (C5aR1). C5L2: C5a-receptor
2 (C5aR2). Apob: apolipoprotein B. DAF1: Decay accelerating factor 1 or CD55 (blocks alternative pathway). mCd59 ab: inhibitor of membrane attack complex assembly.
CR2:complement receptor 2. Crry: complement receptor 1 related gene/protein Y.
Table 2
Selected experimental studies documenting the role of TLRs in atherosclerosis.






LPS challenge Inflammatory gene expression
and plaque composition




Liu 2010 [195] Rat VSMC Human recombinant CRP
and TLR4 small-interfering RNA
Inflammatory response CRP mediates pro-inflammatory
actions via TLR4 signaling.




in adipose tissue inflammation
Hayashi 2012 [197] ApoE.TLR4/mice Infected with an oral pathogen Aortic atheroma TLR4 is atheroprotective in oral
pathogen induced atherosclerosis
Curtiss 2012 [198] Ldlr.TLR1/ and Ldlr.TLR6/ mice High fat diet and challenged with
TLR2/1 and TLR2/6 ligands
Aortic atheroma TLR1 and-6 deficiency were
neutral. TLR2/1 and 6 ligands
increased atherosclerosis.
Karper 2012 [199] ApoE3 Leiden mice Femoral artery cuff and TLR7/9
antagonists.
TLR7/9 expression. Vascular




and foam cell formation
Polykratis 2012 [200] ApoE/ mice with endothelial
and myeloid cell TRAF6 deficiency
High fat diet Aortic atheroma TRAF6 induce pro-atherogenous
changes in endothelial but not in
myeloid cells in which TRAF6
signaling is anti-inflammatory
and anti-atherogenous.
Koulis 2014 [201] ApoE/.TLR9/ High fat diet Aortic atheroma TLR9 protects against atherosclerosis
Abbreviations: Ldlr: LDL-receptor. LPS: lipopolysaccharide. ABCG1 ATP-binding cassette transporter G1. HDL: High-density cholesterol. TLR: Toll-like receptor. VCMC:
Vascular smooth muscle cell. CRP: C-reactive protein. RNA: Ribonucleic acid. ApoE: apolipoprotein E. TRAF6: tumor necrosis factor receptoreassociated factor 6.
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including TLR1, TLR2 and TLR4 [139e141]. The role of TLRs in the
development of atherosclerosis appears to be complex. For
example, expression of TLR2 on endothelial cells seems to pro-
mote atherosclerosis, whereas it has protective effects when
expressed on myeloid cells [142]. Furthermore TLR3, TLR7, andTLR9 may protect against atherosclerosis in mice [143]. Thus,
anaphylatoxin receptors and different types of TLRs seem to be
upregulated in atherosclerotic tissues indicating a plausible
connection to the inflammatory component of atherosclerosis.
This should be further explored as possible therapeutical targets in
atherosclerosis.
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Previous epidemiological studies have indicated that the com-
plement system is associated with development of atherosclerosis
and serum C3 and C4 levels have been linked to an increased risk
for cardiovascular diseases [144e148]. It has also been demon-
strated that an increased ratio of C3/C4 is predictive for new cor-
onary events in a group of patients with former coronary events
[149].
Hertle et al. studied persons with increased risk of atheroscle-
rosis and found that plasma C3a was associated with an increase in
carotid intima media thickness in the population as a whole, and in
heavy smokers C3a was associated with overt cardiovascular dis-
ease [150]. Angiographic lumen loss detected by coronary angiog-
raphy 6e8 months after percutaneous coronary intervention (PCI)
with drug eluting stents (DES) was associated with higher levels of
C3a and C5a at baseline [28]. Very recently a positive correlation
between the anaphylatoxin receptors C3aR and C5aR and platelet
activation in coronary artery disease was detected [151].
In a study of 50 patients with MI, it was shown that monocytes
from MI patients compared to cells from healthy controls showed
increased expression of TLR2, in particular in patients with
accompanying cardiogenic shocks [152]. The monocyte expression
of TLR2 was associated with circulating levels of systemic inflam-
mation. Other TLRs were, however, not investigated [152].
Studying coronary thrombi in acute coronary syndromes, it was
found that myeloid related proteins were ligands for TLR4, leading
to a downstream pro-inflammatory response [153]. Consequently,
TLR4 expression on monocytes was increased in patients with MI
compared to controls, and in patients with MI and heart failure,
TLR4 expression and corresponding pro-inflammatory cytokines
were even more increased [154]. Another group found an increase
in TLR4 expression on monocytes in patients with AMI, and it was
demonstrated that TLR4 to a larger degree was expressed on
CD14 þ CD16 þ cells [155]. Furthermore, in a study of 70 patients
with stable angina, a significant correlation between the severity of
coronary stenosis and the TLR2 and TLR4 response in monocytes
was demonstrated, and two hours after PCI there was a significant
decrease in these responses [156]. Thus, similar results have been
obtained in both stable and unstable coronary syndromes. Finally,
stimulating blood from patients with stable angina with lipopoly-
saccharide (a TLR4 ligand), resulted in increases in TNFa and IL-6
compared to normal controls, however the response did not
reflect disease severity [157].
So, in patients with clinical coronary artery disease the com-
plement system is activated, especially through the proin-
flammatory anaphylatoxins, mirroring the atherosclerotic process.
The TLRs are also activated in overt coronary artery disease, mainly
through TLR4, hence it would be prudent to explore this further in
clinical trials.
7. Genetic studies of innate immunity in human
atherosclerosis
C4A and C4B are two genes encoding complement factor 4, a
protein participating in the initial activation of CP and LP. Both
genes are present in most individuals, but the number of copies
varies. A genetic linkage study found that a low number of C4B
copies is a risk factor for short term mortality in MI patients who
are smokers [158].
Patients with systemic inflammatory diseases, including rheu-
matoid arthritis and systemic lupus erythematosus (SLE), have
increased risk for atherosclerotic diseases [159]. Interestingly, it
was found that both elevated and lowered levels of MBL were
associated with increased carotid intima media thickness inrheumatoid arthritis as compared to thosewithmediumMBL levels
[160], illustrating the double-edged sword of complement activity.
However, MBL (MBL2) genotypes have not been predictive for
coronary artery disease in statin treated patients [161]. Low MBL2
genotype, but not total serum MBL concentration, was associated
with cardiovascular events in type 2 diabetics in South Asia [162]. In
a large Caucasian population, MBL2 polymorphisms related to MBL
deficiency were associated with increased risk for MI [163]. A
similar association betweenMBL deficiency and arterial thrombosis
has been demonstrated in SLE [164]. In patients with type 2 dia-
betes and MI, high levels of soluble TCC predicted future cardio-
vascular events, and low levels of MASP-2 at admittance predicted
poorer prognosis [165]. In contrast, a recent study showing
different levels of MASP-2 and other MASP molecules in cardio-
vascular disease compared to controls, could not document a cor-
relation between the concentration and disease outcome [166].
Lastly, in a genetic linkage study, the C5 rs17611 GG genotype
correlated with levels of circulating C5a, indicating increased risk
for outcome in patients with known carotid atherosclerosis [167]. It
has been reported that CH50 and small high-density lipoprotein
(HDL) particles were associated with subclinical atherosclerosis in
patients with SLE [168]. However, whereas CH50 can measure
functional complement capacity, it is not an accurate method of
measuring complement activation, making interpretation of this
study difficult.
Age-related macular degeneration (AMD) is a common disease
that clearly is linked to complement dysregulation [169]. AMD and
atherosclerosis may share partially overlapping pathogenesis. A
non-synonymous SNP (rs1061170/Y402H) in the FH gene encoding
FH is robustly associated with increased risk of AMD, however, no
association to cardiovascular events has been demonstrated [169].
This at least suggests, that it is not genetically determined dysre-
gulation of the AP that is the most important factor in complement-
dependent atherogenesis. In a large multicentre study with pa-
tients with familiar hypercholesterolemia, presence of the Y402H
polymorphism in the FH gene was associated with a two-fold
reduction in risk of cardiovascular disease [170].
No association was found between genetic variations in TLR4 or
TLR2 and carotid intima media thickness in a large community
population [171]. However a very recent study has documented
that TLR4 is upregulated in stroke patients, and furthermore indi-
cating that polymorphisms in the TLR4 gene promoter region in-
fluences TLR4 gene expression [172]. A genetic variation in the TLR4
gene was found to be associated with reduced risk for MI [173], and
it has been reported that SNP1350 T/C in the TLR2 gene was less
frequent in patients with MI and hypertension, suggesting a
possible protective effect of this SNP [174].
8. Human interventional studies
As C5-inhibitors have been shown to reduce atherosclerosis in
murine models indicating C5 as a possible therapeutic target
[175,176], several groups have studied inhibition of cleavage of C5
into C5a and C5b, in humans. Two early trials tested pexelizumab, a
precursor of the recombinant anti-C5 antibody eculizumab, in
coronary artery bypass grafting (CABG) with results indicating
reduced mortality [177,178]. However, a recent study, combining
results from the two trials including more than 7000 CABG patients
found only a non-significant 6.7% reduction in 30-days mortality
[52]. Nevertheless, there was a mortality benefit for high-risk sur-
gical patients in an explanatory analysis of the combined data [179].
In a systematic overview from 2006, Mahaffey et al. found that
pexelizumab reduced 30-day mortality in patients with acute MI
[180]. In 2008, Testa et al. published a larger meta-analysis
including more than 15,000 patients with STEMI or undergoing
A. Hovland et al. / Atherosclerosis 241 (2015) 480e494490CABG [51]. There was no survival benefit for the group as a whole,
but a significant reduction in mortality in the CABG group. Thus, C5
inhibitors have so far yielded disappointing results when used in
patients with acute coronary events. However, it should be
emphasized that pexelizumab was administered after some delay
in most of the trials, and a recent study documented that the effect
of C5 inhibitionwas not satisfactory since an increase in soluble TCC
was found prior to infusion of the drug, possibly explaining the lack
of effect [181].
Notably, no long-time effects of complement inhibition on
development of atherosclerosis have been reported. Genetic com-
plement deficient patients, except for MBL, are so scarce that
clinical intervention studies in these patients have been impossible.
Furthermore, no clinical interventional studies targeting TLRs have
been performed. However, in a study on murine and human
monocytes, inhibition of TLR2 and CD14 (co-receptor of TLR4) by a
small oxidized phospholipid leads to reduction of downstream
inflammatory cytokines [182]. The same small molecule fed to
rabbits reduced atherosclerosis [182]. Thus, it remains to be shown
whether TLR-targeted strategies e either alone or combined with
complement inhibitors - will prevent human atherosclerosis.
9. Concluding remarks and future perspectives
There is abundant evidence that the innate immune system,
including the complement system, the TLRs and the inflamma-
some, is an essential player in inflammation in general, whether
this is induced by exogenous PAMPs like in infection, or by
endogenous DAMPs like in sterile inflammation [183], the latter of
particular importance for atherosclerosis. We have put forward a
hypothesis that combined inhibition of key “bottle necks” mole-
cules in the complement system (e.g. C3 or C5) and in the TLR-
family (co-receptor CD14), acting early in the recognition phase,
might be a novel general therapeutic regimen in various inflam-
matory disease conditions whether induced by PAMPS or DAMPS
[184]. Animal studies using the combined inhibitory approach in
experimental atherosclerosis are still missing and highly war-
ranted, as are studies with refined human models. Thus, future
studies are needed to test the hypothesis that upstreammodulation
of complement and TLRs might be a rationale for treatment of
atherosclerosis in humans (Fig. 3).
Acknowledgments
We thank Scott Leighton, CMI, Medicus Media for creating the
illustrations.
References
[1] P.A. Heidenreich, J.G. Trogdon, O.A. Khavjou, J. Butler, K. Dracup,
M.D. Ezekowitz, E.A. Finkelstein, Y. Hong, S.C. Johnston, A. Khera, D.M. Lloyd-
Jones, S.A. Nelson, G. Nichol, D. Orenstein, P.W. Wilson, Y.J. Woo, Council on
cardiovascular surgery and anesthesia, and interdisciplinary council on
quality of care and outcomes research. Forecasting the future of cardiovas-
cular disease in the United States: a policy statement from the American
Heart Association, Circulation 123 (2011) 933e944.
[2] G.K. Hansson, P. Libby, The immune response in atherosclerosis: a double-
edged sword, Nat. Rev. Immunol. 6 (2006) 508e519.
[3] G.K. Hansson, A. Hermansson, The immune system in atherosclerosis, Nat.
Immunol. 12 (2011) 204e212.
[4] D. Steinberg, Atherogenesis in perspective: hypercholesterolemia and
inflammation as partners in crime, Nat. Med. 8 (2002) 1211e1217.
[5] K. Skålen, K. Gustafsson, E.K. Rydberg, L. Mattson Hulten, O. Wiklund,
T.L. Innerarity, J. Boren, Subendothelial retention of atherogenic lipoproteins
in early atherosclerosis, Nature 417 (2002) 750e754.
[6] I. Tabas, K.J. Williams, J. Boren, Subendothelial lipoprotein retention as the
initiating process in atherosclerosis: update and therapeutic implications,
Circulation 116 (2007) 1832e1844.
[7] H. Ait-Oufella, S. Taleb, Z. Mallat, A. Tedgui, Recent advances on the role of
cytokines in atherosclerosis, Arterioscler. Thromb. Vasc. Biol. 31 (2011)969e979.
[8] J. Frostegård, A.K. Ulfgren, P. Nyberg, U. Hedin, J. Swedenborg, U. Andersson,
G.K. Hansson, Cytokine expression in advanced human atherosclerotic pla-
ques: dominance of pro-inflammatory (Th1) and macrophage-stimulating
cytokines, Atherosclerosis 145 (1999) 33e43.
[9] T. Kyaw, P. Tipping, B.H. Toh, A. Bobik, Current understanding of the role of B
cell subsets and intimal and adventitial B cells in atherosclerosis, Curr. Opin.
Lipidol. 22 (2011) 373e379.
[10] P. Ponnuswamy, E.A. Van Vre, Z. Mallat, A. Tedgui, Humoral and cellular
immune responses in atherosclerosis: spotlight on B- and T-cells, Vasc.
Pharmacol. 56 (2012) 193e203.
[11] M. Wigren, J. Nilsson, D. Kolbus, Lymphocytes in atherosclerosis, Clin. Chim.
Acta 413 (2012) 1562e1568.
[12] S. Colin, G. Chinetti-Gbaguidi, B. Staels, Macrophage phenotypes in athero-
sclerosis, Immunol. Rev. 262 (2014) 153e166.
[13] H.J. Medbury, H. Williams, J.P. Fletcher, Clinical significance of macrophage
phenotypes in cardiovascular disease, Clin. Transl. Med. 3 (2014) 63.
[14] D.M. Mosser, J.P. Edwards, Exploring the full spectrum of macrophage acti-
vation, Nat. Rev. Immunol. 8 (2008) 958e969.
[15] J.J. Boyle, M. Johns, T. Kampfer, A.T. Nguyen, L. Game, D.J. Schaer, J.C. Mason,
D.O. Haskard, Activating transcription factor 1 directs Mhem atheropro-
tective macrophages through coordinated iron handling and foam cell pro-
tection, Circ. Res. 110 (2012) 20e33.
[16] C. Erbel, M. Tyka, C.M. Helmes, M. Akhavanpoor, G. Rupp, G. Domschke,
F. Linden, A. Wolf, A. Doesch, F. Lasitschka, H.A. Katus, C.A. Gleissner, CXCL4-
induced plaque macrophages can be specifically identified by co-expression
of MMP7þS100A8þ in vitro and in vivo, Innate Immun. 21 (2015) 255e265.
[17] C.C. Ruan, Q. Ge, Y. Li, X.D. Li, D.R. Chen, K.D. Ji, Y.J. Wu, L.J. Sheng, C. Yan,
D.L. Zhu, P.J. Gao, Complement-mediated macrophage polarization in peri-
vascular adipose tissue contributes to vascular injury in deoxycorticosterone
acetate-salt mice, Arterioscler. Thromb. Vasc. Biol. 35 (2015) 598e606.
[18] C. Weber, H. Noels, Atherosclerosis: current pathogenesis and therapeutic
options, Nat. Med. 17 (2011) 1410e1422.
[19] I. Gonçalves, M.L. Gronholdt, I. S€oderberg, M.P. Ares, B.G. Nordestgaard,
J.F. Bentzon, G.N. Fredrikson, J. Nilsson, Humoral immune response against
defined oxidized low-density lipoprotein antigens reflects structure and
disease activity of carotid plaques, Arterioscler. Thromb. Vasc. Biol. 25 (2005)
1250e1255.
[20] K. Hartvigsen, M.Y. Chou, L.F. Hansen, P.X. Shaw, S. Tsimikas, C.J. Binder,
J.L. Witztum, The role of innate immunity in atherogenesis, J. Lipid Res. 50
(Suppl. l) (2009) S388eS393.
[21] M.C. Carroll, D.E. Isenman, Regulation of humoral immunity by complement,
Immunity 37 (2012) 199e207.
[22] M. Kolev, G. Le Friec, C. Kemper, The role of complement in CD4(þ) T cell
homeostasis and effector functions, Semin. Immunol. 25 (2013) 12e19.
[23] W.K. den Dekker, C. Cheng, G. Pasterkamp, H.J. Duckers, Toll like receptor 4
in atherosclerosis and plaque destabilization, Atherosclerosis 209 (2010)
314e320.
[24] A.M. Lundberg, Z.Q. Yan, Innate immune recognition receptors and damage-
associated molecular patterns in plaque inflammation, Curr. Opin. Lipidol. 22
(2011) 343e349.
[25] D.L. Mann, The emerging role of innate immunity in the heart and vascular
system: for whom the cell tolls, Circ. Res. 108 (2011) 1133e1145.
[26] A.N. Seneviratne, B. Sivagurunathan, C. Monaco, Toll-like receptors and
macrophage activation in atherosclerosis, Clin. Chim. Acta 413 (2012) 3e14.
[27] D.O. Haskard, J.J. Boyle, J.C. Mason, The role of complement in atheroscle-
rosis, Curr. Opin. Lipidol. 19 (2008) 478e482.
[28] W.S. Speidl, K.M. Katsaros, S.P. Kastl, G. Zorn, K. Huber, G. Maurer, J. Wojta,
G. Christ, Coronary late lumen loss of drug eluting stents is associated with
increased serum levels of the complement components C3a and C5a,
Atherosclerosis 208 (2010) 285e289.
[29] M. Torzewski, S. Bhakdi, Complement and atherosclerosis-united to the
point of no return? Clin. Biochem. 46 (2013) 20e25.
[30] J. Bordet, Les leukocytes et les proprietes actives du serum chez les vaccines,
Ann. Inst. Pasteur 9 (1895) 462e506.
[31] M.J. Walport, Complement. First of two parts, N. Engl. J. Med. 344 (2001)
1058e1066.
[32] M.J. Walport, Complement. Second of two parts, N. Engl. J. Med. 344 (2001)
1140e1144.
[33] D. Ricklin, G. Hajishengallis, K. Yang, J.D. Lambris, Complement: a key system
for immune surveillance and homeostasis, Nat. Immunol. 11 (2010)
785e797.
[34] P. Geertinger, H. Sorensen, Complement and arteriosclerosis, Atherosclerosis
18 (1973) 65e71.
[35] P.S. Seifert, M.D. Kazatchkine, The complement system in atherosclerosis,
Atherosclerosis 73 (1988) 91e104.
[36] P. Garred, C. Honore, Y.J. Ma, L. Munthe-Fog, T. Hummelshøj, MBL2, FCN1,
FCN2 and FCN3-The genes behind the initiation of the lectin pathway of
complement, Mol. Immunol. 46 (2009) 2737e2744.
[37] Y.J. Ma, M.O. Skjoedt, P. Garred, Collectin-11/MASP complex formation
triggers activation of the lectin complement pathwayethe fifth lectin
pathway initiation complex, J. Innate Immun. 5 (2013) 242e250.
[38] B.P. Morgan, Complement membrane attack on nucleated cells: resistance,
recovery and non-lethal effects, Biochem. J. 264 (1989) 1e14.
[39] M. Huber-Lang, J.V. Sarma, F.S. Zetoune, D. Rittirsch, T.A. Neff, S.R. McGuire,
A. Hovland et al. / Atherosclerosis 241 (2015) 480e494 491J.D. Lambris, R.L. Warner, M.A. Flierl, L.M. Hoesel, F. Gebhard, J.G. Younger,
S.M. Drouin, R.A. Wetsel, P.A. Ward, Generation of C5a in the absence of C3: a
new complement activation pathway, Nat. Med. 12 (2006) 682e687.
[40] A. Clark, A. Weymann, E. Hartman, Y. Turmelle, M. Carroll, J.M. Thurman,
V.M. Holers, D.E. Hourcade, D.A. Rudnick, Evidence for non-traditional acti-
vation of complement factor C3 during murine liver regeneration, Mol.
Immunol. 45 (2008) 3125e3132.
[41] U. Amara, D. Rittirsch, M. Flierl, U. Bruckner, A. Klos, F. Gebhard, J.D. Lambris,
M. Huber-Lang, Interaction between the coagulation and complement sys-
tem, Curr. Top. Complement II (2009) 68e76.
[42] M.J. Krisinger, V. Goebeler, Z. Lu, S.C. Meixner, T. Myles, E.L. Pryzdial,
E.M. Conway, Thrombin generates previously unidentified C5 products that
support the terminal complement activation pathway, Blood 120 (2012)
1717e1725.
[43] J.P. Atkinson, T.H. Goodship, Complement factor H and the hemolytic uremic
syndrome, J. Exp. Med. 204 (2007) 1245e1248.
[44] L. Luzzatto, G. Gianfaldoni, Recent advances in biological and clinical aspects
of paroxysmal nocturnal hemoglobinuria, Int. J. Hematol. 84 (2006)
104e112.
[45] M. Cicardi, K. Bork, T. Caballero, T. Craig, H.H. Li, H. Longhurst, A. Reshef,
B. Zuraw, HAWK (Hereditary Angioedema International Working Group).
Evidence-based recommendations for the therapeutic management of
angioedema owing to hereditary C1 inhibitor deficiency: consensus report of
an International Working Group, Allergy 67 (2012) 147e157.
[46] C.J. Parker, Paroxysmal nocturnal hemoglobinuria, Curr. Opin. Hematol. 19
(2012) 141e148.
[47] K.T. Lappegård, D. Christiansen, A. Pharo, E.B. Thorgersen, B.C. Hellerud,
J. Lindstad, E.W. Nielsen, G. Bergseth, D. Fadnes, T.G. Abrahamsen, E.A. Høiby,
L. Schejbel, P. Garred, J.D. Lambris, M. Harboe, T.E. Mollnes, Human genetic
deficiencies reveal the roles of complement in the inflammatory network:
lessons from nature, Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 15861e15866.
[48] L. Schejbel, D. Fadnes, H. Permin, K.T. Lappegård, P. Garred, T.E. Mollnes,
Primary complement C5 deficiencies - molecular characterization and clin-
ical review of two families, Immunobiology 218 (2013) 1304e1310.
[49] D. Ricklin, J.D. Lambris, Complement in immune and inflammatory disorders:
therapeutic interventions, J. Immunol. 190 (2013) 3839e3847.
[50] H.F. Weisman, T. Bartow, M.K. Leppo, H.C. Marsh, G.R. Carson, M.F. Concino,
M.P. Boyle, K.H. Roux, M.L. Weisfeldt, D.T. Fearon, Soluble human comple-
ment receptor type 1: in vivo inhibitor of complement suppressing post-
ischemic myocardial inflammation and necrosis, Science 249 (1990)
146e151.
[51] L. Testa, W.J. Van Gaal, R. Bhindi, G.G. Biondi-Zoccai, A. Abbate, P. Agostoni,
I. Porto, F. Andreotti, F. Crea, A.P. Banning, Pexelizumab in ischemic heart
disease: a systematic review and meta-analysis on 15,196 patients, J. Thorac.
Cardiovasc Surg. 136 (2008) 884e893.
[52] P.K. Smith, S.K. Shernan, J.C. Chen, M. Carrier, E.D. Verrier, P.X. Adams,
T.G. Todaro, L.H. Muhlbaier, J.H. Levy, PRIMO-CABG II Investigators. Effects of
C5 complement inhibitor pexelizumab on outcome in high-risk coronary
artery bypass grafting: combined results from the PRIMO-CABG I and II trials,
J. Thorac. Cardiovasc Surg. 142 (2011) 89e98.
[53] P. Broz, D.M. Monack, Newly described pattern recognition receptors team
up against intracellular pathogens, Nat. Rev. Immunol. 13 (2013) 551e565.
[54] R. Medzhitov, C.A. Janeway, Decoding the patterns of self and nonself by the
innate immune system, Science 296 (2002) 298e300.
[55] P. Matzinger, An innate sense of danger, Semin. Immunol. 10 (1998)
399e415.
[56] Z.L. Chang, Important aspects of Toll-like receptors, ligands and their
signaling pathways, Inflamm. Res. 59 (2010) 791e808.
[57] T. Kawai, S. Akira, The role of pattern-recognition receptors in innate im-
munity: update on Toll-like receptors, Nat. Immunol. 11 (2010) 373e384.
[58] E. Latz, A. Visintin, E. Lien, K.A. Fitzgerald, B.G. Monks, E.A. Kurt-Jones,
D.T. Golenbock, T. Espevik, Lipopolysaccharide rapidly traffics to and from
the Golgi apparatus with the toll-like receptor 4-MD-2-CD14 complex in a
process that is distinct from the initiation of signal transduction, J. Biol.
Chem. 277 (2002) 47834e47843.
[59] J.C. Kagan, R. Medzhitov, Phosphoinositide-mediated adaptor recruitment
controls Toll-like receptor signaling, Cell 125 (2006) 943e955.
[60] O. Halaas, H. Husebye, T. Espevik, The journey of Toll-like receptors in the
cell, Adv. Exp. Med. Biol. 598 (2007) 35e48.
[61] J.C. Kagan, T. Su, T. Horng, A. Chow, S. Akira, R. Medzhitov, TRAM couples
endocytosis of Toll-like receptor 4 to the induction of interferon-beta, Nat.
Immunol. 9 (2008) 361e368.
[62] N.J. Nilsen, G.I. Vladimer, J. Stenvik, M.P. Orning, M.V. Zeid-Kilani, M. Bugge,
B. Bergstroem, J. Conlon, H. Husebye, A.G. Hise, K.A. Fitzgerald, T. Espevik,
E. Lien, A role for the adaptor proteins TRAM and TRIF in toll-like receptor 2
signaling, J. Biol. Chem. 290 (2015) 3209e3222.
[63] R.M. Vabulas, P. Ahmad-Nejad, C. da Costa, T. Miethke, C.J. Kirschning,
H. H€acker, H. Wagner, Endocytosed HSP60s use toll-like receptor 2 (TLR2)
and TLR4 to activate the toll/interleukin-1 receptor signaling pathway in
innate immune cells, J. Biol. Chem. 276 (2001) 31332e31339.
[64] M.F. Roelofs, W.C. Boelens, L.A.B. Joosten, S. Abdollahi-Roodsaz, J. Geurts,
L.U. Wunderink, B.W. Schreurs, W.B. van den Berg, T.R.D.J. Radstake, Iden-
tification of small heat shock protein B8 (HSP22) as a novel TLR4 ligand and
potential Involvement in the pathogenesis of rheumatoid arthritis,
J. Immunol. 176 (2006) 7021e7027.[65] M.A. Chase, D.S. Wheeler, K.M. Lierl, V.S. Hughes, H.R. Wong, K. Page, Hsp72
induces inflammation and regulates cytokine production in Airway Epithe-
lium through a TLR4- and NF- b-dependent mechanism, J. Immunol. 179
(2007) 6318e6324.
[66] Y. Yang, B. Liu, J. Dai, P.K. Srivastava, D.J. Zammit, L. Lefrançois, Z. Li, Heat
shock protein gp96 is a master chaperone for toll-like receptors and is
important in the innate function of macrophages, Immunity 26 (2007)
215e226.
[67] H. Fang, Y. Wu, X. Huang, W. Wang, B. Ang, X. Cao, T. Wan, Toll-like receptor
4 (TLR4) is essential for Hsp70-like protein 1 (HSP70L1) to activate dendritic
cells and induce Th1 response, J. Biol. Chem. 286 (2011) 30393e30400.
[68] M. Yu, H. Wang, A. Ding, D.T. Golenbock, E. Latz, C.J. Czura, M.J. Fenton,
K.J. Tracey, H. Yang, HMGB1 signals through toll-like receptor (TLR) 4 and
TLR2, Shock 26 (2006) 174e179.
[69] H.S. Hreggvidsdottir, T. Ostberg, H. W€ah€amaa, H. Schierbeck, A.C. Aveberger,
L. Klevenvall, K. Palmblad, L. Ottosson, U. Andersson, H.E. Harris, The alarmin
HMGB1 acts in synergy with endogenous and exogenous danger signals to
promote inflammation, J. Leukoc. Biol. 86 (2009) 655e662.
[70] K. Peter, A. Bobik, HMGB1 signals danger in acute coronary syndrome:
emergence of a new risk marker for cardiovascular death? Atherosclerosis
221 (2012) 317e318.
[71] P. Holvoet, P.C. Davey, D. De Keyzer, M. Doukoure, E. Deridder,
M.L. Bochaton-Piallat, G. Gabbiani, E. Beaufort, K. Bishay, N. Andrieux,
N. Benhabiles, G. Marguerie, Oxidized low-density lipoprotein correlates
positively with toll-like receptor 2 and interferon regulatory factor-1 and
inversely with superoxide dismutase-1 expression: studies in hypercholes-
terolemic swine and THP-1 cells, Arterioscler. Thromb. Vasc. Biol. 26 (2006)
1558e1565.
[72] C.R. Stewart, L.M. Stuart, K. Wilkinson, J.M. van Gils, J. Deng, A. Halle,
K.J. Rayner, L. Boyer, R. Zhong, W.A. Frazier, A. Lacy-Hulbert, J. El Khoury,
D.T. Golenbock, K.J. Moore, CD36 ligands promote sterile inflammation
through assembly of a Toll-like receptor 4 and 6 heterodimer, Nat. Immunol.
11 (2010) 155e161.
[73] M. Falck-Hansen, C. Kassiteridi, C. Monaco, Toll-like receptors in athero-
sclerosis, Int. J. Mol. Sci. 14 (2013) 14008e14023.
[74] M.F. Tsan, B. Gao, Endogenous ligands of Toll-like receptors, J. Leukoc. Biol.
76 (2004) 514e519.
[75] T. Kawai, S. Akira, Toll-like receptors and their crosstalk with other innate
receptors in infection and immunity, Immunity 34 (2011) 637e650.
[76] C.C. Lee, A.M. Avalos, H.L. Ploegh, Accessory molecules for toll-like receptors
and their function, Nat. Rev. Immunol. 12 (2012) 168e179.
[77] M. Estruch, C. Bancells, L. Beloki, J.L. Sanchez-Quesada, J. Ordo~nez-Llanos,
S. Benitez, CD14 and TLR4 mediate cytokine release promoted by electro-
negative LDL in monocytes, Atherosclerosis 229 (2013) 356e362.
[78] E. Latz, T.S. Xiao, A. Stutz, Activation and regulation of the inflammasomes,
Nat. Rev. Immunol. 13 (2013) 397e411.
[79] P. Duewell, H. Kono, K.J. Rayner, C.M. Sirois, G. Vladimer, F.G. Bauernfeind,
G.S. Abela, L. Franchi, G. Nu~nez, M. Schnurr, T. Espevik, E. Lien, K.A. Fitzgerald,
K.L. Rock, K.J. Moore, S.D. Wright, V. Hornung, E. Latz, NLRP3 inflammasomes
are required for atherogenesis and activated by cholesterol crystals, Nature
464 (2010) 1357e1361.
[80] K. Rajam€aki, J. Lappalainen, K. O€orni, E. V€alim€aki, S. Matikainen, P.T. Kovanen,
K.K. Eklund, Cholesterol crystals activate the NLRP3 inflammasome in human
macrophages: a novel link between cholesterol metabolism and inflamma-
tion, PLoS One 5 (2010) e11765.
[81] F.J. Sheedy, A. Grebe, K.J. Rayner, P. Kalantari, B. Ramkhelawon,
S.B. Carpenter, C.E. Becker, H.N. Ediriweera, A.E. Mullick, D.T. Golenbock,
L.M. Stuart, E. Latz, K.A. Fitzgerald, K.J. Moore, CD36 coordinates NLRP3
inflammasome activation by facilitating intracellular nucleation of soluble
ligands into particulate ligands in sterile inflammation, Nat. Immunol. 14
(2013) 812e820.
[82] P.M. Ridker, C.P. Howard, V. Walter, B. Everett, P. Libby, J. Hensen, T. Thuren,
on behalf of the CANTOS Pilot Investigative Group, Effects of Interleukin-1b
inhibition with canakinumab on Hemoglobin A1c, lipids, c-reactive protein,
Interleukin-6, and Fibrinogen: a phase IIb randomized, placebo-controlled
trial, Circulation 126 (2012) 2739e2748.
[83] S. Freigang, F. Ampenberger, A. Weiss, T.D. Kanneganti, Y. Iwakura,
M. Hersberger, M. Kopf, Fatty acid-induced mitochondrial uncoupling elicits
inflammasome-independent IL-1a and sterile vascular inflammation in
atherosclerosis, Nat. Immunol. 14 (2013) 1045e1053.
[84] M. Wang, J.L. Krauss, H. Domon, K.B. Hosur, S. Liang, P. Magotti,
M. Triantafilou, K. Triantafilou, J.D. Lambris, G. Hajishengallis, Microbial
hijacking of complement-toll-like receptor crosstalk, Sci. Signal 3 (2010)
ra11.
[85] G. Hajishengallis, J.D. Lambris, Crosstalk pathways between Toll-like re-
ceptors and the complement system, Trends Immunol. 31 (2010) 154e163.
[86] W.C. Song, Crosstalk between complement and toll-like receptors, Toxicol.
Pathol. 40 (2012) 174e182.
[87] A. Barratt-Due, S.E. Pischke, O.L. Brekke, E.B. Thorgersen, E.W. Nielsen,
T. Espevik, M. Huber-Lang, T.E. Mollnes, Bride and groom in systemic
inflammationethe bells ring for complement and Toll in cooperation,
Immunobiology 217 (2012) 1047e1056.
[88] S.J. DiMartino, W. Yuan, P. Redecha, L.B. Ivashkiv, J.E. Salmon, Insoluble im-
mune complexes are most effective at triggering IL-10 production in human
monocytes and synergize with TLR ligands and C5a, Clin. Immunol. 127
A. Hovland et al. / Atherosclerosis 241 (2015) 480e494492(2008) 56e65.
[89] N. Okazaki, K. Hazeki, T. Izumi, K. Nigorikawa, O. Hazeki, C5a controls TLR-
induced IL-10 and IL-12 production independent of phosphoinositide 3-
kinase, J. Biochem. 149 (2011) 265e274.
[90] A.C. Raby, B. Holst, J. Davies, C. Colmont, Y. Laumonnier, B. Coles, S. Shah,
J. Hall, N. Topley, J. K€ohl, B.P. Morgan, M.O. Labeta, TLR activation enhances
C5a-induced pro-inflammatory responses by negatively modulating the
second C5a receptor, C5L2, Eur. J. Immunol. 41 (2011) 2741e2752.
[91] C. Lau, S. Nygård, H. Fure, O.K. Olstad, M. Holden, K.T. Lappegård, O.L. Brekke,
T. Espevik, E. Hovig, T.E. Mollnes, CD14 and complement crosstalk and
Largely mediate the Transcriptional response to Escherichia coli in human
whole blood as revealed by DNA microarray, PLoS One 10 (2015) e0117261.
[92] X. Zhang, Y. Kimura, C. Fang, L. Zhou, G. Sfyroera, J.D. Lambris, R.A. Wetsel,
T. Miwa, W.C. Song, Regulation of Toll-like receptor-mediated inflammatory
response by complement in vivo, Blood 110 (2007) 228e236.
[93] L. Zou, Y. Feng, Y. Li, M. Zhang, C. Chen, J. Cai, Y. Gong, L. Wang, J.M. Thurman,
X. Wu, J.P. Atkinson, W. Chao, Complement factor B is the downstream
effector of TLRs and plays an important role in a mouse model of severe
sepsis, J. Immunol. 191 (2013) 5625e5635.
[94] C. Han, J. Jin, S. Xu, H. Liu, N. Li, X. Cao, Integrin CD11b negatively regulates
TLR-triggered inflammatory responses by activating Syk and promoting
degradation of MyD88 and TRIF via Cbl-b, Nat. Immunol. 11 (2010) 734e742.
[95] T.K. Means, A.D. Luster, Integrins limit the Toll, Nat. Immunol. 11 (2010)
691e693.
[96] B. Holst, A.C. Raby, J.E. Hall, M.O. Labeta, Complement takes its Toll: an in-
flammatory crosstalk between Toll-like receptors and the receptors for the
complement anaphylatoxin C5a, Anaesthesia 67 (2012) 60e64.
[97] K. Triantafilou, T.R. Hughes, M. Triantafilou, B.P. Morgan, The complement
membrane attack complex triggers intracellular Ca2þ fluxes leading to
NLRP3 inflammasome activation, J. Cell. Sci. 126 (2013) 2903e2913.
[98] E. Asgari, G. Le Friec, H. Yamamoto, E. Perucha, S.S. Sacks, J. K€ohl, H.T. Cook,
C. Kemper, C3a modulates IL-1b secretion in human monocytes by regulating
ATP efflux and subsequent NLRP3 inflammasome activation, Blood 122
(2013) 3473e3481.
[99] E.O. Samstad, N. Niyonzima, S. Nymo, M.H. Aune, L. Ryan, S.S. Bakke,
K.T. Lappegård, O.L. Brekke, J.D. Lambris, J.K. Damås, E. Latz, T.E. Mollnes,
T. Espevik, Cholesterol crystals induce complement-dependent inflamma-
some activation and cytokine release, J. Immunol. 192 (2014) 2837e2845.
[100] M.M. Markiewski, B. Nilsson, K.N. Ekdahl, T.E. Mollnes, J.D. Lambris, Com-
plement and coagulation: strangers or partners in crime? Trends Immunol.
28 (2007) 184e192.
[101] U. Amara, M.A. Flierl, D. Rittirsch, A. Klos, H. Chen, B. Acker, U.B. Brückner,
B. Nilsson, F. Gebhard, J.D. Lambris, M. Huber-Lang, Molecular intercom-
munication between the complement and coagulation systems, J. Immunol.
185 (2010) 5628e5636.
[102] A. Verschoor, H.F. Langer, Crosstalk between platelets and the complement
system in immune protection and disease, Thromb. Haemost. 110 (2013)
910e919.
[103] A.P. Owens, F.H. Passam, S. Antoniak, S.M. Marshall, A.L. McDaniel, L. Rudel,
J.C. Williams, B.K. Hubbard, J.A. Dutton, J. Wang, P.S. Tobias, L.K. Curtiss,
A. Daugherty, D. Kirchhofer, J.P. Luyendyk, P.M. Moriarty, S. Nagarajan,
B.C. Furie, B. Furie, D.G. Johns, R.E. Temel, N. Mackman, Monocyte tissue
factor-dependent activation of coagulation in hypercholesterolemic mice
and monkeys is inhibited by simvastatin, J. Clin. Invest 122 (2012) 558e568.
[104] A. Barbu, O.A. Hamad, L. Lind, K.N. Ekdahl, B. Nilsson, The role of complement
factor C3 in lipid metabolism, Mol. Immunol. 67 (1) (2015) 101e107.
[105] G. Hajishengallis, J.D. Lambris, Microbial manipulation of receptor crosstalk
in innate immunity, Nat. Rev. Immunol. 11 (2011) 187e200.
[106] L.E. Reddick, N.M. Alto, Bacteria fighting back: how pathogens target and
subvert the host innate immune system, Mol. Cell. 54 (2014) 321e328.
[107] O.L. Brekke, D. Christiansen, H. Fure, M. Fung, T.E. Mollnes, The role of
complement C3 opsonization, C5a receptor, and CD14 in E. coli-induced up-
regulation of granulocyte and monocyte CD11b/CD18 (CR3), phagocytosis,
and oxidative burst in human whole blood, J. Leukoc. Biol. 81 (2007)
1404e1413.
[108] O.L. Brekke, D. Christiansen, H. Fure, A. Pharo, M. Fung, J. Riesenfeld,
T.E. Mollnes, Combined inhibition of complement and CD14 abolish E. coli-
induced cytokine-, chemokine- and growth factor-synthesis in human
whole blood, Mol. Immunol. 45 (2008) 3804e3813.
[109] B. Salvesen, M. Fung, O.D. Saugstad, T.E. Mollnes, Role of complement and
CD14 in meconium-induced cytokine formation, Pediatrics 121 (2008)
e496ee505.
[110] A. Barratt-Due, E.B. Thorgersen, K. Egge, S. Pischke, A. Sokolov, B.C. Hellerud,
J.K. Lindstad, A. Pharo, A.K. Bongoni, R. Rieben, M. Nunn, H. Scott,
T.E. Mollnes, Combined inhibition of complement (C5) and CD14 markedly
attenuates inflammation, Thrombogenicity, and hemodynamic changes in
porcine sepsis, J. Immunol. 191 (2013) 819e827.
[111] R.B. Jennings, Historical perspective on the pathology of myocardial
ischemia/reperfusion injury, Circ. Res. 113 (2013) 428e438.
[112] H. Zhao, J.S. Perez, K. Lu, A.J. George, D. Ma, Role of toll-like receptor-4 in
renal graft ischemia-reperfusion injury, Am. J. Physiol. Ren. Physiol. 306
(2014) F801eF811.
[113] J. Damman, M.R. Daha, W.J. van Son, H.G. Leuvenink, R.J. Ploeg, M.A. Seelen,
Crosstalk between complement and toll-like receptor activation in relation
to donor brain death and renal ischemia-reperfusion injury, Am. J. Transpl.11 (2011) 660e669.
[114] R. Saba, D.L. Sorensen, S.A. Booth, MicroRNA-146a: a dominant, negative
regulator of the innate immune response, Front. Immunol. 5 (2014) 578.
[115] S. Pareek, S. Roy, B. Kumari, P. Jain, A. Banerjee, S. Vrati, MiR-155 induction in
microglial cells suppresses Japanese encephalitis virus replication and
negatively modulates innate immune responses, J. Neuroinflammation 11
(2014) 97.
[116] M.T. Eadon, A. Jacob, P.N. Cunningham, R.J. Quigg, J.G. Garcia, J.J. Alexander,
Transcriptional profiling reveals that C5a alters microRNA in brain endo-
thelial cells, Immunology 143 (2014) 363e373.
[117] G.D. Norata, F. Sala, A.L. Catapano, C. Fernandez-Hernando, MicroRNAs and
lipoproteins: a connection beyond atherosclerosis? Atherosclerosis 227
(2013) 209e215.
[118] L. Francescut, T. Steiner, S. Byrne, K. Cianflone, S. Francis, C. Stover, The role
of complement in the development and manifestation of murine atherogenic
inflammation: novel avenues, J. Innate Immun. 4 (2012) 260e272.
[119] G. Wu, W. Hu, A. Shahsafaei, W. Song, M. Dobarro, G.K. Sukhova,
R.R. Bronson, G.P. Shi, R.P. Rother, J.A. Halperin, X. Qin, Complement regu-
lator CD59 protects against atherosclerosis by restricting the formation of
complement membrane attack complex, Circ. Res. 104 (2009) 550e558.
[120] W. Schmiedt, R. Kinscherf, -P. Deigner, H. Kamencic, O. Nauen, J. Kilo,
H. Oelert, J. Metz, S. Bhakdi, Complement C6 deficiency protects against diet-
induced atherosclerosis in rabbits, Arterioscler. Thromb. Vasc. Biol. 18 (1998)
1790e1795.
[121] S. Patel, E.M. Thelander, M. Hernandez, J. Montenegro, H. Hassing, C. Burton,
S. Mundt, A. Hermanowski-Vosatka, S.D. Wright, Y.S. Chao, P.A. Detmers,
ApoE(-/-) mice develop atherosclerosis in the absence of complement
component C5, Biochem. Biophys. Res. Commun. 286 (2001) 164e170.
[122] P. Hasselbacher, J. Hahn, In vitro effects of radiographic contrast media on
the complement system, J. Allergy Clin. Immunol. 66 (1980) 217e222.
[123] S. Nymo, N. Niyonzima, T. Espevik, T.E. Mollnes, Cholesterol crystal-induced
endothelial cell activation is complement-dependent and mediated by TNF,
Immunobiology 219 (2014) 786e792.
[124] M. Subramanian, E. Thorp, G.K. Hansson, I. Tabas, Treg-mediated suppression
of atherosclerosis requires MYD88 signaling in DCs, J. Clin. Invest 123 (2013)
179e188.
[125] M. Yu, H. Zhou, J. Zhao, N. Xiao, S. Roychowdhury, D. Schmitt, B. Hu,
C.V. Harding, A.G. Hise, S.L. Hazen, A.L. Defranco, P.L. Fox, R.E. Morton,
P.E. Dicorleto, M. Febbraio, L.E. Nagy, J.D. Smith, J.A. Wang, X. Li, MyD88-
dependent interplay between myeloid and endothelial cells in the initia-
tion and progression of obesity-associated inflammatory diseases, J. Exp.
Med. 211 (2014) 887e907.
[126] H.S. Warren, R.G. Tompkins, L.L. Moldawer, J. Seok, W. Xu, M.N. Mindrinos,
R.V. Maier, W. Xiao, R.W. Davis, Mice are not men, Proc. Natl. Acad. Sci. U. S.
A. 112 (2015) E345.
[127] P. Libby, P.M. Ridker, G.K. Hansson, Progress and challenges in translating the
biology of atherosclerosis, Nature 473 (2011) 317e325.
[128] S. Bhakdi, M. Torzewski, M. Klouche, M. Hemmes, Complement and
atherogenesis : binding of CRP to Degraded, Nonoxidized LDL enhances
complement activation, Arterioscler. Thromb. Vasc. Biol. 19 (1999)
2348e2354.
[129] S. Bhakdi, M. Torzewski, K. Paprotka, S. Schmitt, H. Barsoom, P. Suriyaphol,
S.R. Han, K.J. Lackner, M. Husmann, Possible protective role for C-reactive
protein in atherogenesis: complement activation by modified lipoproteins
halts before detrimental terminal sequence, Circulation 109 (2004)
1870e1876.
[130] D.A. Fraser, A.J. Tenner, Innate immune proteins C1q and mannan-binding
lectin enhance clearance of atherogenic lipoproteins by human monocytes
and macrophages, J. Immunol. 185 (2010) 3932e3939.
[131] L. Chavez-Sanchez, A. Madrid-Miller, K. Chavez-Rueda, M.V. Legorreta-
Haquet, E. Tesoro-Cruz, F. Blanco-Favela, Activation of TLR2 and TLR4 by
minimally modified low-density lipoprotein in human macrophages and
monocytes triggers the inflammatory response, Hum. Immunol. 71 (2010)
737e744.
[132] X. Su, L. Ao, Y. Shi, T.R. Johnson, D.A. Fullerton, X. Meng, Oxidized low density
lipoprotein induces bone morphogenetic protein-2 in coronary artery
endothelial cells via Toll-like receptors 2 and 4, J. Biol. Chem. 286 (2011)
12213e12220.
[133] M.J. Smolinska, T.H. Page, A.M. Urbaniak, B.E. Mutch, N.J. Horwood, Hck
tyrosine kinase regulates TLR4-induced TNF and IL-6 production via AP-1,
J. Immunol. 187 (2011) 6043e6051.
[134] D.A. Mogilenko, I.V. Kudriavtsev, A.S. Trulioff, V.S. Shavva, E.B. Dizhe,
B.V. Missyul, A.V. Zhakhov, A.M. Ischenko, A.P. Perevozchikov, S.V. Orlov,
Modified low density lipoprotein stimulates complement C3 expression and
secretion via liver X receptor and Toll-like receptor 4 activation in human
macrophages, J. Biol. Chem. 287 (2012) 5954e5968.
[135] R. Oksjoki, P. Laine, S. Helske, P. Vehmaan-Kreula, M.I. M€ayr€anp€a€a, P. Gasque,
P.T. Kovanen, M.O. Pentik€ainen, Receptors for the anaphylatoxins C3a and
C5a are expressed in human atherosclerotic coronary plaques, Atheroscle-
rosis 195 (2007) 90e99.
[136] S. Vijayan, Y. Asare, J. Grommes, O. Soehnlein, E. Lutgens, G. Shagdarsuren,
A. Togtokh, M. Jacobs, J.W. Fischer, J. Bernhagen, C. Weber, A. Schober,
E. Shagdarsuren, High expression of C5L2 correlates with high proin-
flammatory cytokine expression in advanced human atherosclerotic plaques,
Am. J. Pathol. 184 (2014) 2123e2133.
A. Hovland et al. / Atherosclerosis 241 (2015) 480e494 493[137] S. Helske, R. Oksjoki, K.A. Lindstedt, J. Lommi, H. Turto, K. Werkkala,
M. Kupari, P.T. Kovanen, Complement system is activated in stenotic aortic
valves, Atherosclerosis 196 (2008) 190e200.
[138] M. ter Weeme, A.B. Vonk, K. Kupreishvili, M. van Ham, S. Zeerleder,
D. Wouters, W. Stooker, L. Eijsman, V.W. Van Hinsbergh, P.A. Krijnen,
H.W. Niessen, Activated complement is more extensively present in diseased
aortic valves than naturally occurring complement inhibitors: a sign of
ongoing inflammation, Eur. J. Clin. Invest 40 (2010) 4e10.
[139] H. Xu, K. Shah, E. Faure, O. Equils, L. Thomas, C. Fishbein, D. Luthringer,
-P. Xu, B. Rajavashisth, J. Yano, S. Kaul, M. Arditi, Toll-like Receptor-4 is
expressed by macrophages in murine and human lipid-rich atherosclerotic
plaques and upregulated by oxidized LDL, Circulation 104 (2001)
3103e3108.
[140] K. Edfeldt, J. Swedenborg, G.K. Hansson, Z.Q. Yan, Expression of toll-like
receptors in human atherosclerotic lesions: a possible pathway for plaque
activation, Circulation 105 (2002) 1158e1161.
[141] R. Malgor, P.M. Bhatt, B.A. Connolly, D.L. Jacoby, K.J. Feldmann, M.J. Silver,
M. Nakazawa, K.D. McCall, D.J. Goetz, Wnt5a, TLR2 and TLR4 are elevated in
advanced human atherosclerotic lesions, Inflamm. Res. 63 (2014) 277e285.
[142] A.E. Mullick, K. Soldau, W.B. Kiosses, T.A. Bell, P.S. Tobias, L.K. Curtiss,
Increased endothelial expression of Toll-like receptor 2 at sites of disturbed
blood flow exacerbates early atherogenic events, J. Exp. Med. 205 (2008)
373e383.
[143] P. Libby, A.H. Lichtman, G.K. Hansson, Immune effector mechanisms impli-
cated in atherosclerosis: from mice to humans, Immunity 38 (2013)
1092e1104.
[144] V. Capuano, T. D'Arminio, G. La Sala, G. Mazzotta, The third component of the
complement (C3) is a marker of the risk of atherogenesis, Eur. J. Cardiovasc
Prev. Rehabil. 13 (2006) 658e660.
[145] G. Engstr€om, B. Hedblad, L. Janzon, F. Lindg€arde, Complement C3 and C4 in
plasma and incidence of myocardial infarction and stroke: a population-
based cohort study, Eur. J. Cardiovasc Prev. Rehabil. 14 (2007) 392e397.
[146] M.M. van Greevenbroek, M. Jacobs, C.J. van der Kallen, V.M. Vermeulen,
E.H. Jansen, C.G. Schalkwijk, I. Ferreira, E.J. Feskens, C.D. Stehouwer, The
cross-sectional association between insulin resistance and circulating com-
plement C3 is partly explained by plasma alanine aminotransferase, inde-
pendent of central obesity and general inflammation (the CODAM study),
Eur. J. Clin. Invest 41 (2011) 372e379.
[147] N. Wlazlo, M.M. van Greevenbroek, I. Ferreira, E.J. Jansen, E.J. Feskens, C.J. van
der Kallen, C.G. Schalkwijk, B. Bravenboer, C.D. Stehouwer, Low-grade
inflammation and insulin resistance independently explain substantial parts
of the association between body fat and serum C3: the CODAM study,
Metabolism 61 (2012) 1787e1796.
[148] B. Nilsson, O.A. Hamad, H. Ahlstr€om, J. Kullberg, L. Johansson, L. Lindhagen,
A. Haenni, K.N. Ekdahl, L. Lind, C3 and C4 are strongly related to Adipose
tissue variables and cardiovascular risk factors, Eur. J. Clin. Invest 44 (2014)
587e596.
[149] A. Palikhe, J. Sinisalo, M. Sepp€anen, H. Haario, S. Meri, V. Valtonen,
M.S. Nieminen, M.L. Lokki, Serum complement C3/C4 ratio, a novel marker
for recurrent cardiovascular events, Am. J. Cardiol. 99 (2007) 890e895.
[150] E. Hertle, M. van Greevenbroek, I.C. Arts, C.J. van der Kallen, S.L. Geijselaers,
E.J. Feskens, E.H. Jansen, C.G. Schalkwijk, C.D. Stehouwer, Distinct associa-
tions of complement C3a and its precursor C3 with atherosclerosis and
cardiovascular disease. The CODAM study, Thromb. Haemost. 111 (2014)
1102e1111.
[151] J. Patzelt, K.A. Mueller, S. Breuning, A. Karathanos, R. Schleicher, P. Seizer,
M. Gawaz, H.F. Langer, T. Geisler, Expression of anaphylatoxin receptors on
platelets in patients with coronary heart disease, Atherosclerosis 238 (2015)
289e295.
[152] S. Selejan, J. P€oss, F. Walter, M. Hohl, R. Kaiser, A. Kazakov, M. B€ohm, A. Link,
Ischaemia-induced up-regulation of Toll-like receptor 2 in circulating
monocytes in cardiogenic shock, Eur. Heart J. 33 (2012) 1085e1094.
[153] K. Yonekawa, M. Neidhart, L.A. Altwegg, C.A. Wyss, R. Corti, T. Vogl,
M. Grigorian, S. Gay, T.F. Lüscher, W. Maier, Myeloid related proteins activate
Toll-like receptor 4 in human acute coronary syndromes, Atherosclerosis
218 (2011) 486e492.
[154] M. Satoh, Y. Shimoda, C. Maesawa, T. Akatsu, Y. Ishikawa, Y. Minami,
K. Hiramori, M. Nakamura, Activated toll-like receptor 4 in monocytes is
associated with heart failure after acute myocardial infarction, Int. J. Cardiol.
109 (2006) 226e234.
[155] M. Kashiwagi, T. Imanishi, Y. Ozaki, K. Satogami, T. Masuno, T. Wada,
Y. Nakatani, K. Ishibashi, K. Komukai, T. Tanimoto, Y. Ino, H. Kitabata,
T. Akasaka, Differential expression of Toll-like receptor 4 and human
monocyte subsets in acute myocardial infarction, Atherosclerosis 221 (2012)
249e253.
[156] D. Versteeg, I.E. Hoefer, A.H. Schoneveld, D.P. de Kleijn, E. Busser, C. Strijder,
M. Emons, P.R. Stella, P.A. Doevendans, G. Pasterkamp, Monocyte toll-like
receptor 2 and 4 responses and expression following percutaneous coro-
nary intervention: association with lesion stenosis and fractional flow
reserve, Heart 94 (2008) 770e776.
[157] E.H. Elsenberg, J.E. Sels, M.A. Hillaert, A.H. Schoneveld, N.A. van den Dungen,
T.C. van Holten, M. Roest, J.W. Jukema, A.J. van Zonneveld, P.G. de Groot,
N. Pijls, G. Pasterkamp, I.E. Hoefer, Increased cytokine response after toll-like
receptor stimulation in patients with stable coronary artery disease,
Atherosclerosis 231 (2013) 346e351.[158] B. Blasko, R. Kolka, P. Thorbjornsdottir, S.T. Sigurdarson, G. Sigurdsson,
Z. Ronai, M. Sasvari-Szekely, S. B€odvarsson, G. Thorgeirsson, Z. Prohaszka,
M. Kovacs, G. Füst, G.J. Arason, Low complement C4B gene copy number
predicts short-term mortality after acute myocardial infarction, Int. Immu-
nol. 20 (2008) 31e37.
[159] D.P. Symmons, S.E. Gabriel, Epidemiology of CVD in rheumatic disease, with
a focus on RA and SLE, Nat. Rev. Rheumatol. 7 (2011) 399e408.
[160] L.N. Troelsen, P. Garred, B. Christiansen, C. Torp-Pedersen, I.J. Christensen,
E. Narvestad, S. Jacobsen, Double role of mannose-binding lectin in relation
to carotid intima-media thickness in patients with rheumatoid arthritis, Mol.
Immunol. 47 (2010) 713e718.
[161] A. Alipour, M.C. Cabezas, J.W. Elte, J.C. Vallve, J. Ribalta, A.H. Zwinderman,
J.C. Defesche, J.W. Jukema, Mannose binding lectin 2 haplotypes do not affect
the progression of coronary atherosclerosis in men with proven coronary
artery disease treated with pravastatin, Atherosclerosis 215 (2011) 125e129.
[162] M.A. Siezenga, P.K. Shaw, M.R. Daha, T.J. Rabelink, S.P. Berger, Low Mannose-
Binding Lectin (MBL) genotype is associated with future cardiovascular
events in type 2 diabetic South Asians. A prospective cohort study, Car-
diovasc Diabetol. 10 (2011) 60.
[163] I.T. Vengen, H.O. Madsen, P. Garred, C. Platou, L. Vatten, V. Videm, Mannose-
binding lectin deficiency is associated with myocardial infarction: the
HUNT2 study in Norway, PLoS One 7 (2012) e42113.
[164] T. Øhlenschlaeger, P. Garred, H.O. Madsen, S. Jacobsen, Mannose-binding
lectin variant alleles and the risk of arterial thrombosis in systemic lupus
erythematosus, N. Engl. J. Med. 351 (2004) 260e267.
[165] L.G. Mellbin, M. Bjerre, S. Thiel, T.K. Hansen, Complement activation and
prognosis in patients with type 2 diabetes and myocardial infarction: a
report from the DIGAMI 2 trial, Diabetes Care 35 (2012) 911e917.
[166] V. Frauenknecht, S. Thiel, L. Storm, N. Meier, M. Arnold, J.P. Schmid, H. Saner,
V. Schroeder, Plasma levels of mannan-binding lectin (MBL)-associated
serine proteases (MASPs) and MBL-associated protein in cardio- and cere-
brovascular diseases, Clin. Exp. Immunol. 173 (2013) 112e120.
[167] M. Hoke, W. Speidl, M. Schillinger, E. Minar, S. Zehetmayer, M. Sch€onherr,
O. Wagner, C. Mannhalter, Polymorphism of the complement 5 gene and
cardiovascular outcome in patients with atherosclerosis, Eur. J. Clin. Invest
42 (2012) 921e926.
[168] S. Parra, G. Vives, R. Ferre, M. Gonzalez, M. Guardiola, J. Ribalta, A. Castro,
Complement system and small HDL particles are associated with subclinical
atherosclerosis in SLE patients, Atherosclerosis 225 (2012) 224e230.
[169] R. Sofat, J.P. Casas, M. Kumari, P.J. Talmud, H. Ireland, M. Kivimaki,
M. Marmot, A.D. Hughes, S. Thom, S. Ebrahim, J.C. Whittaker, L. Smeeth,
D.A. Lawlor, S.E. Humphries, A.D. Hingorani, Genetic variation in comple-
ment factor H and risk of coronary heart disease: eight new studies and a
meta-analysis of around 48,000 individuals, Atherosclerosis 213 (2010)
184e190.
[170] K.C. Koeijvoets, S.P. Mooijaart, G.M. Dallinga-Thie, J.C. Defesche,
E.W. Steyerberg, R.G. Westendorp, J.J. Kastelein, P.M. van Hagen,
E.J. Sijbrands, Complement factor H Y402H decreases cardiovascular disease
risk in patients with familial hypercholesterolaemia, Eur. Heart J. 30 (2009)
618e623.
[171] R. Labrum, S. Bevan, M. Sitzer, M. Lorenz, H.S. Markus, Toll receptor poly-
morphisms and carotid artery intima-media thickness, Stroke 38 (2007)
1179e1184.
[172] S. Ferronato, M. Gomez-Lira, M. Menegazzi, E. Diani, S. Olivato, M. Sartori,
A. Scuro, G. Malerba, P.F. Pignatti, M.G. Romanelli, S. Mazzucco, Poly-
morphism -2604G>A variants in TLR4 promoter are associated with
different gene expression level in peripheral blood of atherosclerotic pa-
tients, J. Hum. Genet. 58 (2013) 812e814.
[173] D.A. Enquobahrie, N.L. Smith, J.C. Bis, C.L. Carty, K.M. Rice, T. Lumley,
L.A. Hindorff, R.N. Lemaitre, M.A. Williams, D.S. Siscovick, S.R. Heckbert,
B.M. Psaty, Cholesterol ester transfer protein, interleukin-8, peroxisome
proliferator activator receptor alpha, and Toll-like receptor 4 genetic varia-
tions and risk of incident nonfatal myocardial infarction and ischemic stroke,
Am. J. Cardiol. 101 (2008) 1683e1688.
[174] A. Dzumhur, L. Zibar, J. Wagner, T. Simundic, Z. Dembic, J. Barbic, Association
studies of gene polymorphisms in toll-like receptors 2 and 4 in croatian
patients with acute myocardial infarction, Scand. J. Immunol. 75 (2012)
517e523.
[175] X. Lu, M. Xia, V. Endresz, I. Faludi, L. Mundkur, E. Gonczol, D. Chen,
V.V. Kakkar, Immunization with a combination of 2 peptides derived from
the C5a receptor significantly reduces early atherosclerotic lesion in
Ldlrtm1Her Apobtm2SgyJ mice, Arterioscler. Thromb. Vasc. Biol. 32 (2012)
2358e2371.
[176] E. Shagdarsuren, K. Bidzhekov, S.F. Mause, S. Simsekyilmaz, T. Polakowski,
H. Hawlisch, J.E. Gessner, A. Zernecke, C. Weber, C5a receptor targeting in
neointima formation after arterial injury in atherosclerosis-prone mice,
Circulation 122 (2010) 1026e1036.
[177] S.K. Shernan, J.C. Fitch, N.A. Nussmeier, J.C. Chen, S.A. Rollins, C.F. Mojcik,
K.J. Malloy, T.G. Todaro, T. Filloon, S.W. Boyce, D.M. Gangahar, M. Goldberg,
L.J. Saidman, D.T. Mangano, Pexelizumab study Investigators. Impact of
pexelizumab, an anti-C5 complement antibody, on total mortality and
adverse cardiovascular outcomes in cardiac surgical patients undergoing
cardiopulmonary bypass, Ann. Thorac. Surg. 77 (2004) 942e949 discussion
949e50.
[178] E.D. Verrier, S.K. Shernan, K.M. Taylor, F. Van de Werf, M.F. Newman,
A. Hovland et al. / Atherosclerosis 241 (2015) 480e494494J.C. Chen, M. Carrier, A. Haverich, K.J. Malloy, P.X. Adams, T.G. Todaro,
C.F. Mojcik, S.A. Rollins, J.H. Levy, PRIMO-CABG Investigators. Terminal
complement blockade with pexelizumab during coronary artery bypass graft
surgery requiring cardiopulmonary bypass: a randomized trial, JAMA 291
(2004) 2319e2327.
[179] P.W. Armstrong, C.B. Granger, P.X. Adams, C. Hamm, D. Holmes,
W.W. O'Neill, T.G. Todaro, A. Vahanian, F. Van de Werf, Pexelizumab for
acute ST-elevation myocardial infarction in patients undergoing primary
percutaneous coronary intervention: a randomized controlled trial, JAMA
297 (2007) 43e51.
[180] K.W. Mahaffey, F. Van de Werf, S.K. Shernan, C.B. Granger, E.D. Verrier,
T.G. Filloon, T.G. Todaro, P.X. Adams, J.H. Levy, V. Hasselblad, P.W. Armstrong,
Effect of pexelizumab on mortality in patients with acute myocardial
infarction or undergoing coronary artery bypass surgery: a systematic
overview, Am. Heart J. 152 (2006) 291e296.
[181] C. Martel, C.B. Granger, M. Ghitescu, A. Stebbins, A. Fortier, P.W. Armstrong,
A. Bonnefoy, P. Theroux, Pexelizumab fails to inhibit assembly of the ter-
minal complement complex in patients with ST-elevation myocardial
infarction undergoing primary percutaneous coronary intervention. Insight
from a substudy of the Assessment of Pexelizumab in Acute Myocardial
Infarction (APEX-AMI) trial, Am. Heart J. 164 (2012) 43e51.
[182] I. Mendel, E. Feige, N. Yacov, Y. Salem, I. Levi, O. Propheta-Meiran, A. Shoham,
E. Ishai, J. George, D. Harats, E. Breitbart, VB-201, an oxidized phospholipid
small molecule, inhibits CD14- and Toll-like receptor-2-dependent innate
cell activation and constrains atherosclerosis, Clin. Exp. Immunol. 175 (2014)
126e137.
[183] G.Y. Chen, G. Nu~nez, Sterile inflammation: sensing and reacting to damage,
Nat. Rev. Immunol. 10 (2010) 826e837.
[184] T.E. Mollnes, D. Christiansen, E.O.L. Brekke, T. Espevik, Hypothesis: combined
inhibition of complement and CD14 as treatment regimen to attenuate the
inflammatory response, Adv. Exp. Med. Biol. 632 (2008) 253e263.
[185] V.K. Bhatia, S. Yun, V. Leung, D.C. Grimsditch, G.M. Benson, M.B. Botto,
J.J. Boyle, D.O. Haskard, Complement C1q reduces early atherosclerosis in
low-density lipoprotein receptor-deficient mice, Am. J. Pathol. 170 (2007)
416e426.
[186] M.J. Lewis, T.H. Malik, M.R. Ehrenstein, J.J. Boyle, M. Botto, D.O. Haskard,
Immunoglobulin M is required for protection against atherosclerosis in low-
density lipoprotein receptor-deficient mice, Circulation 120 (2009)
417e426.
[187] R.A. Matthijsen, M.P. de Winther, D. Kuipers, I. van der Made, C. Weber,
M.V. Herias, M.J. Gijbels, W.A. Buurman, Macrophage-specific expression of
mannose-binding lectin controls atherosclerosis in low-density lipoprotein
receptor-deficient mice, Circulation 119 (2009) 2188e2195.
[188] F. Orsini, P. Villa, S. Parrella, R. Zangari, E.R. Zanier, R. Gesuete, M. Stravalaci,
S. Fumagalli, R. Ottria, J.J. Reina, A. Paladini, E. Micotti, R. Ribeiro-Viana,
J. Rojo, V.I. Pavlov, G.L. Stahl, A. Bernardi, M. Gobbi, M.G. De Simoni, Targeting
mannose-binding lectin confers long-lasting protection with a surprisingly
wide therapeutic window in cerebral ischemia, Circulation 126 (2012)
1484e1494.
[189] T.H. Malik, A. Cortini, D. Carassiti, J.J. Boyle, D.O. Haskard, M. Botto, The
alternative pathway is critical for pathogenic complement activation in
endotoxin- and diet-induced atherosclerosis in low-density lipoproteinreceptor-deficient mice, Circulation 122 (2010) 1948e1956.
[190] H.D. Manthey, A.C. Thomas, I.A. Shiels, A. Zernecke, T.M. Woodruff, B. Rolfe,
S.M. Taylor, Complement C5a inhibition reduces atherosclerosis in ApoE/
mice, FASEB J. 25 (2011) 2447e2455.
[191] M. Sakuma, T. Morooka, Y. Wang, C. Shi, K. Croce, H. Gao, M. Strainic,
M.E. Medof, D.I. Simon, The Intrinsic complement regulator decay-
accelerating factor modulates the biological response to vascular injury,
Arterioscler. Thromb. Vasc. Biol. 30 (2010) 1196e202.
[192] R.D. Lewis, M.J. Perry, I.A. Guschina, C.L. Jackson, B.P. Morgan, T.R. Hughes,
CD55 deficiency protects against atherosclerosis in ApoE-deficient mice via
C3a modulation of lipid metabolism, Am. J. Pathol. 179 (2011) 1601e1607.
[193] F. Liu, L. Wu, G. Wu, C. Wang, L. Zhang, S. Tomlinson, X. Qin, Targeted mouse
complement inhibitor CR2-Crry protects against the development of
atherosclerosis in mice, Atherosclerosis 234 (2014) 237e243.
[194] L. Yvan-Charvet, C. Welch, T.A. Pagler, M. Ranalletta, M. Lamkanfi, S. Han,
M. Ishibashi, R. Li, N. Wang, A.R. Tall, Increased inflammatory gene expres-
sion in ABC transporter-deficient macrophages: free cholesterol accumula-
tion, increased signaling via toll-like receptors, and neutrophil infiltration of
atherosclerotic lesions, Circulation 118 (2008) 1837e1847.
[195] N. Liu, J. Liu, Y. Ji, P. Lu, Toll-like receptor 4 signaling mediates inflammatory
activation induced by C-reactive protein in vascular smooth muscle cells,
Cell. Physiology Biochem. 25 (2010) 467e476.
[196] Y. Ding, S. Subramanian, V.N. Montes, L. Goodspeed, S. Wang, C. Han,
A.S. Teresa, J. Kim, K.D. O'Brien, A. Chait, Toll-like receptor 4 deficiency de-
creases atherosclerosis but does not protect against inflammation in obese
low-density lipoprotein receptor-deficient mice, Arterioscler. Thromb. Vasc.
Biol. 32 (2012) 1596e1604.
[197] C. Hayashi, G. Papadopoulos, C.V. Gudino, E.O. Weinberg, K.R. Barth,
A.G. Madrigal, Y. Chen, H. Ning, M. LaValley, F.C. Gibson, J.A. Hamilton,
C.A. Genco, Protective role for TLR4 signaling in atherosclerosis progression
as revealed by infection with a common oral pathogen, J. Immunol. 189
(2012) 3681e3688.
[198] L.K. Curtiss, A.S. Black, D.J. Bonnet, P.S. Tobias, Atherosclerosis induced by
endogenous and exogenous toll-like receptor (TLR)1 or TLR6 agonists, J. Lipid
Res. 53 (2012) 2126e2132.
[199] J.C. Karper, M.M. Ewing, K.L. Habets, M.R. de Vries, E.A. Peters, A.M. van
Oeveren-Rietdijk, H.C. de Boer, J.F. Hamming, J. Kuiper, E.R. Kandimalla, N. La
Monica, J.W. Jukema, P.H. Quax, Blocking toll-like receptors 7 and 9 reduces
postinterventional remodeling via reduced macrophage activation, foam cell
formation, and migration, Arterioscler. Thromb. Vasc. Biol. 32 (2012)
e72ee80.
[200] A. Polykratis, G. van Loo, S. Xanthoulea, M. Hellmich, M. Pasparakis, Condi-
tional targeting of tumor necrosis factor receptor-associated factor 6 reveals
opposing functions of toll-like receptor signaling in endothelial and myeloid
cells in a mouse model of atherosclerosis, Circulation 126 (2012)
1739e1751.
[201] C. Koulis, Y.C. Chen, C. Hausding, I. Ahrens, T.S. Kyaw, C. Tay, T. Allen,
K. Jandeleit-Dahm, M.J. Sweet, S. Akira, A. Bobik, K. Peter, A. Agrotis, Pro-
tective role for toll-like receptor-9 in the development of atherosclerosis in
apolipoprotein E-deficient mice, Arterioscler. Thromb. Vasc. Biol. 34 (2014)
516e525.
